CPC Scheme - C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

Version: 2023.08

Loading Scheme...

CPC

COOPERATIVE PATENT CLASSIFICATION

C12N

MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q 1/00) [2022-05]

NOTES

Attention is drawn to Notes (1) to (3) following the title of class C12.
Biocidal, pest repellant, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass A01P.
Therapeutic activity of single-cell proteins or enzymes is further classified in subclass A61P.
When classifying in this subclass, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.
In this subclass, it is desirable to add the indexing codes of subclass C12R.
{Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes.}
{In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of C12N.}

WARNINGS

The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

C12N1/11	covered by	C12N 15/79
C12N1/13	covered by	C12N 15/79
C12N1/15	covered by	C12N 15/80
C12N1/19	covered by	C12N 15/81
C12N1/21	covered by	C12N 15/74
C12N5/02	covered by	C12N 5/0006, C12N 5/04 - C12N 5/166
C12N5/07 - C12N5/095	covered by	C12N 5/06
C12N5/18	covered by	C12N 5/16
C12N5/20	covered by	C12N 5/163
C12N5/22	covered by	C12N 5/16
C12N5/24	covered by	C12N 5/163
C12N5/26	covered by	C12N 5/166
C12N5/28	covered by	C12N 5/166
C12N15/53	covered by	C12N 9/0004
C12N7/01	covered by	C12N 7/00
C12N9/02-C12N9/08	covered by	C12N 9/0004
C12N9/26	covered by	C12N 9/2408
C12N9/28-C12N9/30	covered by	C12N 9/2414 - C12N 9/242
C12N9/32	covered by	C12N 9/2422
C12N9/34	covered by	C12N 9/2428
C12N9/36	covered by	C12N 9/2462
C12N9/38	covered by	C12N 9/2468
C12N9/40	covered by	C12N 9/2465
C12N9/42	covered by	C12N 9/2434
C12N9/44	covered by	C12N 9/2451
C12N9/46	covered by	C12N 9/2454
C12N9/56	covered by	C12N 9/54
C12N9/66	covered by	C12N 9/6448
C12N9/68	covered by	C12N 9/6435
C12N9/70	covered by	C07K 14/3153
C12N9/72	covered by	C12N 9/6462
C12N9/74	covered by	C12N 9/6429
C12N9/76	covered by	C12N 9/6427
C12N15/05	covered by	C12N 5/14
C12N15/06	covered by	C12N 5/16
C12N15/07	covered by	C12N 5/16
C12N15/08	covered by	C12N 5/166
C12N15/12	covered by	C07K 14/435
C12N15/13	covered by	C07K 16/00
C12N15/14	covered by	C07K 14/765
C12N15/15	covered by	C07K 14/81
C12N15/16	covered by	C07K 14/575
C12N15/17	covered by	C07K 14/62
C12N15/18	covered by	C07K 14/61
C12N15/19	covered by	C07K 14/52
C12N15/20	covered by	C07K 14/555
C12N15/21	covered by	C07K 14/56
C12N15/22	covered by	C07K 14/565
C12N15/23	covered by	C07K 14/57
C12N15/24	covered by	C07K 14/54
C12N15/25	covered by	C07K 14/545
C12N15/26	covered by	C07K 14/55
C12N15/27	covered by	C07K 14/53
C12N15/28	covered by	C07K 14/525
C12N15/29	covered by	C07K 14/415
C12N15/30	covered by	C07K 14/44
C12N15/31	covered by	C07K 14/195, C07K 14/005
C12N15/32	covered by	C07K 14/325
C12N15/33	covered by	C07K 14/005
C12N15/34	covered by	C07K 14/01
C12N15/35	covered by	C07K 14/015
C12N15/36	covered by	C07K 14/02
C12N15/37	covered by	C07K 14/025
C12N15/38	covered by	C07K 14/03
C12N15/39	covered by	C07K 14/065
C12N15/40	covered by	C07K 14/08
C12N15/41	covered by	C07K 14/085
C12N15/42	covered by	C07K 14/09
C12N15/43	covered by	C07K 14/105
C12N15/44	covered by	C07K 14/11
C12N15/45	covered by	C07K 14/115
C12N15/46	covered by	C07K 14/14
C12N15/47	covered by	C07K 14/145
C12N15/48	covered by	C07K 14/15
C12N15/49	covered by	C07K 14/155
C12N15/50	covered by	C07K 14/165
C12N15/51	covered by	C07K 14/02, C07K 14/10, C07K 14/18
C12N15/53	covered by	C12N 9/0004
C12N15/54	covered by	C12N 9/10
C12N15/55	covered by	C12N 9/14
C12N15/56	covered by	C12N 9/24
C12N15/57	covered by	C12N 9/48
C12N15/58	covered by	C12N 9/6456
C12N15/59	covered by	C12N 9/6483
C12N15/60	covered by	C12N 9/88
C12N15/61	covered by	C12N 9/90
C12N15/83	covered by	C12N 15/82
C12N15/84	covered by	C12N 15/82

In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

C12N 1/00

Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K 35/66, from algae A61K 36/02, from fungi A61K 36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K 39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor [2021-05]

C12N 1/005

{after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/08} [2016-05]

C12N 1/02

Separating microorganisms from their culture media [2017-08]

C12N 1/04

Preserving or maintaining viable microorganisms (immobilised microorganisms C12N 11/00) [2017-08]

C12N 1/06

Lysis of microorganisms [2017-08]

C12N 1/063

. .

{of yeast} [2013-01]

C12N 1/066

. .

{by physical methods} [2013-01]

C12N 1/08

Reducing the nucleic acid content [2013-01]

C12N 1/10

Protozoa; Culture media therefor [2013-01]

C12N 1/105

. .

{Protozoal isolates} [2021-05]

C12N 1/12

Unicellular algae; Culture media therefor (as new plants A01H 13/00) [2019-02]

C12N 1/125

. .

{Unicellular algae isolates} [2021-05]

C12N 1/14

Fungi (culture of mushrooms A01G 18/00; as new plants A01H 15/00); Culture media therefor [2021-05]

C12N 1/145

. .

{Fungal isolates} [2021-05]

C12N 1/16

. .

Yeasts; Culture media therefor [2013-01]

C12N 1/165

. . .

{Yeast isolates} [2021-05]

C12N 1/18

. . .

Baker's yeast; Brewer's yeast [2013-01]

C12N 1/185

. . . .

{Saccharomyces isolates} [2021-05]

C12N 1/20

Bacteria; Culture media therefor [2021-05]

C12N 1/205

. .

{Bacterial isolates} [2021-05]

C12N 1/22

Processes using, or culture media containing, cellulose or hydrolysates thereof [2013-01]

C12N 1/24

Processes using, or culture media containing, waste sulfite liquor [2013-01]

C12N 1/26

Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms C10G 32/00) [2017-08]

C12N 1/28

. .

aliphatic [2013-01]

C12N 1/30

. . .

having five or less carbon atoms [2013-01]

C12N 1/32

Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆ [2013-01]

C12N 1/34

Processes using foam culture [2013-01]

C12N 1/36

Adaptation or attenuation of cells [2013-01]

C12N 1/38

Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence) [2013-01]

C12N 3/00

Spore forming or isolating processes [2013-01]

C12N 5/00

Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00) [2013-01]

NOTE

In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

C12N 5/0006

{Modification of the membrane of cells, e.g. cell decoration} [2013-01]

C12N 5/0012

{Cell encapsulation} [2013-01]

C12N 5/0018

{Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06)} [2013-01]

C12N 5/0025

. .

{Culture media for plant cell or plant tissue culture} [2013-01]

C12N 5/0031

. .

{Serum-free culture media} [2016-05]

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 5/0037 - C12N 5/0056

C12N 5/0037

. .

{Serum-free medium, which may still contain naturally-sourced components} [2013-01]

C12N 5/0043

. .

{Medium free of human- or animal-derived components} [2013-01]

C12N 5/005

. .

{Protein-free medium} [2013-01]

C12N 5/0056

. .

{Xeno-free medium} [2013-01]

C12N 5/0062

{General methods for three-dimensional culture} [2013-01]

C12N 5/0068

{General culture methods using substrates (for specific animal cell type C12N 5/06)} [2013-01]

C12N 5/0075

. .

{using microcarriers} [2013-01]

C12N 5/0081

{Purging biological preparations of unwanted cells} [2013-01]

C12N 5/0087

. .

{Purging against subsets of blood cells, e.g. purging alloreactive T cells} [2013-01]

C12N 5/0093

. .

{Purging against cancer cells} [2013-01]

C12N 5/04

Plant cells or tissues {(culture media C12N 5/0025)} [2013-01]

C12N 5/06

{Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues A01N 1/02)} [2022-05]

NOTE

{In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.
"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group}

C12N 5/0601

. .

{Invertebrate cells or tissues, e.g. insect cells; Culture media therefor} [2013-01]

C12N 5/0602

. .

{Vertebrate cells} [2013-01]

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

C12N 5/0603

. . .

{Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies} [2013-01]

C12N 5/0604

. . . .

{Whole embryos; Culture medium therefor} [2013-01]

C12N 5/0605

. . . .

{Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly} [2013-01]

C12N 5/0606

. . . .

{Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611, induced pluripotent stem cells C12N 5/0696)} [2013-01]

C12N 5/0607

. . .

{Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)} [2015-09]

C12N 5/0608

. . .

{Germ cells (production of embryos, nuclear transfer A01K 67/027)} [2020-05]

C12N 5/0609

. . . .

{Oocytes, oogonia (fertilised oocytes C12N 5/0604)} [2013-01]

C12N 5/061

. . . .

{Sperm cells, spermatogonia} [2013-01]

C12N 5/0611

. . . .

{Primordial germ cells, e.g. embryonic germ cells [EG]} [2013-01]

C12N 5/0612

. . . .

{sorting of gametes, e.g. according to sex or motility} [2013-01]

C12N 5/0613

. . .

{Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)} [2013-01]

C12N 5/0614

. . . .

{Adrenal gland} [2013-01]

C12N 5/0615

. . . .

{Pineal gland} [2013-01]

C12N 5/0616

. . . .

{Pituitary gland} [2013-01]

C12N 5/0617

. . . .

{Thyroid and parathyroid glands} [2013-01]

C12N 5/0618

. . .

{Cells of the nervous system} [2013-01]

C12N 5/0619

. . . .

{Neurons} [2013-01]

C12N 5/062

. . . .

{Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain} [2013-01]

C12N 5/0621

. . . .

{Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)} [2013-01]

C12N 5/0622

. . . .

{Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells} [2013-01]

C12N 5/0623

. . . .

{Stem cells} [2013-01]

C12N 5/0625

. . .

{Epidermal cells, skin cells; Cells of the oral mucosa} [2013-01]

C12N 5/0626

. . . .

{Melanocytes} [2013-01]

C12N 5/0627

. . . .

{Hair cells} [2013-01]

C12N 5/0628

. . . . .

{Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)} [2013-01]

C12N 5/0629

. . . .

{Keratinocytes; Whole skin} [2013-01]

C12N 5/063

. . . . .

{Kereatinocyte stem cells; Keratinocyte progenitors} [2013-01]

C12N 5/0631

. . . .

{Mammary cells} [2013-01]

C12N 5/0632

. . . .

{Cells of the oral mucosa} [2013-01]

C12N 5/0633

. . . .

{Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands} [2013-01]

C12N 5/0634

. . .

{Cells from the blood or the immune system} [2023-05]

NOTE

Committed progenitors are classified with their progeny

WARNING

Group C12N 5/0634 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0635

. . . .

{B lymphocytes} [2023-05]

WARNING

Group C12N 5/0635 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0636

. . . .

{T lymphocytes} [2023-05]

WARNING

Group C12N 5/0636 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0637

. . . . .

{Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg} [2023-05]

WARNING

Group C12N 5/0637 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0638

. . . . .

{Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} [2023-05]

WARNING

Group C12N 5/0638 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0639

. . . .

{Dendritic cells, e.g. Langherhans cells in the epidermis} [2023-05]

WARNING

Group C12N 5/0639 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/064

. . . . .

{Immunosuppressive dendritic cells} [2023-05]

WARNING

Group C12N 5/064 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0641

. . . .

{Erythrocytes} [2013-01]

C12N 5/0642

. . . .

{Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells} [2013-01]

C12N 5/0643

. . . .

{Osteoclasts} [2013-01]

C12N 5/0644

. . . .

{Platelets; Megakaryocytes} [2013-01]

C12N 5/0645

. . . .

{Macrophages, e.g. Kuepfer cells in the liver; Monocytes} [2023-05]

WARNING

Group C12N 5/0645 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0646

. . . .

{Natural killers cells [NK], NKT cells} [2023-05]

WARNING

Group C12N 5/0646 is impacted by reclassification into groups A61K 39/46, A61K 39/461 - A61K 39/46484, A61K 2239/00 - A61K 2239/59.
All groups listed in this Warning should be considered in order to perform a complete search.

C12N 5/0647

. . . .

{Haematopoietic stem cells; Uncommitted or multipotent progenitors} [2017-02]

C12N 5/0648

. . . .

{Splenocytes} [2013-01]

C12N 5/065

. . . .

{Thymocytes} [2013-01]

C12N 5/0651

. . . .

{Lymph nodes} [2013-01]

C12N 5/0652

. . .

{Cells of skeletal and connective tissues; Mesenchyme} [2013-01]

C12N 5/0653

. . . .

{Adipocytes; Adipose tissue} [2013-01]

C12N 5/0654

. . . .

{Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth} [2013-01]

C12N 5/0655

. . . .

{Chondrocytes; Cartilage} [2013-01]

C12N 5/0656

. . . .

{Adult fibroblasts} [2013-01]

C12N 5/0657

. . . .

{Cardiomyocytes; Heart cells} [2013-01]

C12N 5/0658

. . . .

{Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts} [2013-01]

C12N 5/0659

. . . . .

{Satellite cells} [2013-01]

C12N 5/066

. . . .

{Tenocytes; Tendons, Ligaments} [2013-01]

C12N 5/0661

. . . .

{Smooth muscle cells} [2013-01]

C12N 5/0662

. . . .

{Stem cells} [2013-01]

C12N 5/0663

. . . . .

{Bone marrow mesenchymal stem cells (BM-MSC)} [2013-01]

C12N 5/0664

. . . . .

{Dental pulp stem cells, Dental follicle stem cells} [2013-01]

C12N 5/0665

. . . . .

{Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood} [2013-01]

C12N 5/0666

. . . . .

{Mesenchymal stem cells from hair follicles} [2013-01]

C12N 5/0667

. . . . .

{Adipose-derived stem cells [ADSC]; Adipose stromal stem cells} [2013-01]

C12N 5/0668

. . . . .

{Mesenchymal stem cells from other natural sources} [2013-01]

C12N 5/0669

. . . .

{Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0663)} [2013-01]

C12N 5/067

. . .

{Hepatocytes} [2013-01]

C12N 5/0671

. . . .

{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} [2013-01]

C12N 5/0672

. . . .

{Stem cells; Progenitor cells; Precursor cells; Oval cells} [2013-01]

C12N 5/0676

. . .

{Pancreatic cells} [2013-01]

C12N 5/0677

. . . .

{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} [2013-01]

C12N 5/0678

. . . .

{Stem cells; Progenitor cells; Precursor cells} [2013-01]

C12N 5/0679

. . .

{Cells of the gastro-intestinal tract} [2013-01]

C12N 5/068

. . . .

{Stem cells; Progenitors} [2013-01]

C12N 5/0681

. . .

{Cells of the genital tract; Non-germinal cells from gonads} [2020-05]

C12N 5/0682

. . . .

{Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)} [2013-01]

C12N 5/0683

. . . .

{Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)} [2013-01]

C12N 5/0684

. . .

{Cells of the urinary tract or kidneys} [2013-01]

C12N 5/0685

. . . .

{Bladder epithelial cells} [2013-01]

C12N 5/0686

. . . .

{Kidney cells} [2013-01]

C12N 5/0687

. . . .

{Renal stem cells; Renal progenitors} [2013-01]

C12N 5/0688

. . .

{Cells from the lungs or the respiratory tract} [2013-01]

C12N 5/0689

. . . .

{Stem cells; Progenitors} [2013-01]

C12N 5/069

. . .

{Vascular Endothelial cells} [2013-01]

C12N 5/0691

. . . .

{Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels} [2013-01]

C12N 5/0692

. . . .

{Stem cells; Progenitor cells; Precursor cells} [2013-01]

C12N 5/0693

. . .

{Tumour cells; Cancer cells} [2013-01]

C12N 5/0694

. . . .

{Cells of blood, e.g. leukemia cells, myeloma cells} [2013-01]

C12N 5/0695

. . . .

{Stem cells; Progenitor cells; Precursor cells} [2013-01]

C12N 5/0696

. . .

{Artificially induced pluripotent stem cells, e.g. iPS} [2013-01]

C12N 5/0697

. .

{Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)} [2013-01]

C12N 5/0698

. . .

{Skin equivalents} [2013-01]

C12N 5/10

Cells modified by introduction of foreign genetic material [2020-05]

C12N 5/12

. .

Fused cells, e.g. hybridomas [2013-01]

C12N 5/14

. . .

Plant cells [2013-01]

C12N 5/16

. . .

Animal cells [2013-01]

C12N 5/163

. . . .

{one of the fusion partners being a B or a T lymphocyte} [2013-01]

C12N 5/166

. . . .

{resulting from interspecies fusion} [2013-01]

C12N 7/00

Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00) [2017-08]

WARNING

From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00.

C12N 7/02

Recovery or purification [2013-01]

C12N 7/025

. .

{Packaging cell lines, e.g. transcomplementing cell lines, for production of virus} [2013-01]

C12N 7/04

Inactivation or attenuation; Producing viral sub-units [2013-01]

C12N 7/045

. .

{Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered} [2013-01]

C12N 7/06

. .

{Inactivation or attenuation} by chemical treatment [2013-01]

C12N 7/08

. .

{Inactivation or attenuation} by serial passage of virus [2013-01]

C12N 9/00

Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00) [2017-08]

NOTE

Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

C12N 9/0002

{Antibodies with enzymatic activity, e.g. abzymes} [2016-08]

C12N 9/0004

{Oxidoreductases (1.)} [2013-01]

C12N 9/0006

. .

{acting on CH-OH groups as donors (1.1)} [2013-01]

C12N 9/0008

. .

{acting on the aldehyde or oxo group of donors (1.2)} [2013-01]

C12N 9/001

. .

{acting on the CH-CH group of donors (1.3)} [2013-01]

C12N 9/0012

. .

{acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)} [2013-01]

C12N 9/0014

. . .

{acting on the CH-NH₂ group of donors (1.4)} [2013-01]

C12N 9/0016

. . . .

{with NAD or NADP as acceptor (1.4.1)} [2013-01]

C12N 9/0018

. . . . .

{Phenylalanine dehydrogenase (1.4.1.20)} [2013-01]

C12N 9/002

. . . .

{with a cytochrome as acceptor (1.4.2)} [2013-01]

C12N 9/0022

. . . .

{with oxygen as acceptor (1.4.3)} [2013-01]

C12N 9/0024

. . . . .

{D-Amino acid oxidase (1.4.3.3)} [2013-01]

C12N 9/0026

. . .

{acting on CH-NH groups of donors (1.5)} [2013-01]

C12N 9/0028

. . . .

{with NAD or NADP as acceptor (1.5.1)} [2013-01]

C12N 9/003

. . . . .

{Dihydrofolate reductase [DHFR] (1.5.1.3)} [2013-01]

C12N 9/0032

. . . .

{with oxygen as acceptor (1.5.3)} [2013-01]

C12N 9/0034

. . . . .

{Sarcosine oxidase (1.5.3.1)} [2013-01]

C12N 9/0036

. . .

{acting on NADH or NADPH (1.6)} [2013-01]

C12N 9/0038

. . . .

{with a heme protein as acceptor (1.6.2)} [2013-01]

C12N 9/004

. . . . .

{Cytochrome-b5 reductase (1.6.2.2)} [2013-01]

C12N 9/0042

. . . . .

{NADPH-cytochrome P450 reductase (1.6.2.4)} [2013-01]

C12N 9/0044

. . .

{acting on other nitrogen compounds as donors (1.7)} [2013-01]

C12N 9/0046

. . . .

{with oxygen as acceptor (1.7.3)} [2013-01]

C12N 9/0048

. . . . .

{Uricase (1.7.3.3)} [2013-01]

C12N 9/0051

. .

{acting on a sulfur group of donors (1.8)} [2013-01]

C12N 9/0053

. .

{acting on a heme group of donors (1.9)} [2013-01]

C12N 9/0055

. .

{acting on diphenols and related substances as donors (1.10)} [2013-01]

C12N 9/0057

. . .

{with oxygen as acceptor (1.10.3)} [2013-01]

C12N 9/0059

. . . .

{Catechol oxidase (1.10.3.1), i.e. tyrosinase} [2013-01]

C12N 9/0061

. . . .

{Laccase (1.10.3.2)} [2013-01]

C12N 9/0063

. . . .

{Ascorbate oxidase (1.10.3.3)} [2013-01]

C12N 9/0065

. .

{acting on hydrogen peroxide as acceptor (1.11)} [2013-01]

C12N 9/0067

. .

{acting on hydrogen as donor (1.12)} [2013-01]

C12N 9/0069

. .

{acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)} [2013-01]

C12N 9/0071

. .

{acting on paired donors with incorporation of molecular oxygen (1.14)} [2013-01]

C12N 9/0073

. . .

{with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13} [2013-01]

C12N 9/0075

. . . .

{Nitric-oxide synthase (1.14.13.39)} [2013-01]

C12N 9/0077

. . .

{with a reduced iron-sulfur protein as one donor (1.14.15)} [2013-01]

C12N 9/0079

. . . .

{Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)} [2013-01]

C12N 9/0081

. . . .

{Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)} [2013-01]

C12N 9/0083

. . .

{Miscellaneous (1.14.99)} [2013-01]

C12N 9/0085

. . . .

{Steroid 17 alpha-monooxygenase (1.14.99.9)} [2013-01]

C12N 9/0087

. . . .

{Steroid 21-monooxygenase (1.14.99.10)} [2013-01]

C12N 9/0089

. .

{acting on superoxide as acceptor (1.15)} [2013-01]

C12N 9/0091

. .

{oxidizing metal ions (1.16)} [2013-01]

C12N 9/0093

. .

{acting on CH or CH₂ groups (1.17)} [2013-01]

C12N 9/0095

. .

{acting on iron-sulfur proteins as donor (1.18)} [2013-01]

C12N 9/0097

. .

{acting on reduced flavodoxin as donor (1.19)} [2013-01]

C12N 9/10

Transferases (2.) (ribonucleases C12N 9/22) [2013-01]

C12N 9/1003

. .

{transferring one-carbon groups (2.1)} [2013-01]

C12N 9/1007

. . .

{Methyltransferases (general) (2.1.1.)} [2013-01]

C12N 9/1011

. . . .

{Catechol O-methyltransferase (2.1.1.6)} [2013-01]

C12N 9/1014

. . .

{Hydroxymethyl-, formyl-transferases (2.1.2)} [2013-01]

C12N 9/1018

. . .

{Carboxy- and carbamoyl transferases (2.1.3)} [2013-01]

C12N 9/1022

. .

{transferring aldehyde or ketonic groups (2.2)} [2013-01]

C12N 9/1025

. .

{Acyltransferases (2.3)} [2013-01]

C12N 9/1029

. . .

{transferring groups other than amino-acyl groups (2.3.1)} [2013-01]

C12N 9/1033

. . . .

{Chloramphenicol O-acetyltransferase (2.3.1.28)} [2013-01]

C12N 9/1037

. . . .

{Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase} [2013-01]

C12N 9/104

. . .

{Aminoacyltransferases (2.3.2)} [2013-01]

C12N 9/1044

. . . .

{Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII} [2013-01]

C12N 9/1048

. .

{Glycosyltransferases (2.4)} [2013-01]

C12N 9/1051

. . .

{Hexosyltransferases (2.4.1)} [2013-01]

C12N 9/1055

. . . .

{Levansucrase (2.4.1.10)} [2013-01]

C12N 9/1059

. . . .

{Cellulose synthases (2.4.1.12; 2.4.1.29)} [2013-01]

C12N 9/1062

. . . .

{Sucrose synthase (2.4.1.13)} [2013-01]

C12N 9/1066

. . . .

{Sucrose phosphate synthase (2.4.1.14)} [2013-01]

C12N 9/107

. . . .

{1,4-Alpha-glucan branching enzyme (2.4.1.18)} [2013-01]

C12N 9/1074

. . . .

{Cyclomaltodextrin glucanotransferase (2.4.1.19)} [2013-01]

C12N 9/1077

. . .

{Pentosyltransferases (2.4.2)} [2013-01]

C12N 9/1081

. . .

{transferring other glycosyl groups (2.4.99)} [2013-01]

C12N 9/1085

. .

{transferring alkyl or aryl groups other than methyl groups (2.5)} [2013-01]

C12N 9/1088

. . .

{Glutathione transferase (2.5.1.18)} [2013-01]

C12N 9/1092

. . .

{3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase} [2013-01]

C12N 9/1096

. .

{transferring nitrogenous groups (2.6)} [2013-01]

C12N 9/12

. .

transferring phosphorus containing groups, e.g. kinases (2.7) [2013-01]

C12N 9/1205

. . .

{Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases} [2013-01]

C12N 9/1211

. . . .

{Thymidine kinase (2.7.1.21)} [2013-01]

C12N 9/1217

. . .

{Phosphotransferases with a carboxyl group as acceptor (2.7.2)} [2013-01]

C12N 9/1223

. . .

{Phosphotransferases with a nitrogenous group as acceptor (2.7.3)} [2013-01]

C12N 9/1229

. . .

{Phosphotransferases with a phosphate group as acceptor (2.7.4)} [2013-01]

C12N 9/1235

. . .

{Diphosphotransferases (2.7.6)} [2013-01]

C12N 9/1241

. . .

{Nucleotidyltransferases (2.7.7)} [2013-01]

C12N 9/1247

. . . .

{DNA-directed RNA polymerase (2.7.7.6)} [2013-01]

C12N 9/1252

. . . .

{DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase} [2013-01]

C12N 9/1258

. . . .

{Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase} [2013-01]

C12N 9/1264

. . . .

{DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase} [2013-01]

C12N 9/127

. . . .

{RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase} [2017-01]

C12N 9/1276

. . . .

{RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase} [2013-01]

C12N 9/1282

. . . .

{RNA uridylyltransferase (2.7.7.52)} [2013-01]

C12N 9/1288

. . .

{Transferases for other substituted phosphate groups (2.7.8)} [2013-01]

C12N 9/1294

. . .

{Phosphotransferases with paired acceptors (2.7.9)} [2013-01]

C12N 9/13

. .

{transferring sulfur containing groups (2.8)} [2013-01]

C12N 9/14

Hydrolases (3) [2013-01]

C12N 9/16

. .

acting on ester bonds (3.1) [2013-01]

C12N 9/18

. . .

Carboxylic ester hydrolases {(3.1.1)} [2013-01]

C12N 9/20

. . . .

Triglyceride splitting, e.g. by means of lipase [2013-01]

C12N 9/22

. . .

Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)} [2013-01]

C12N 9/24

. .

acting on glycosyl compounds (3.2) [2013-01]

C12N 9/2402

. . .

{hydrolysing O- and S- glycosyl compounds (3.2.1)} [2013-01]

C12N 9/2405

. . . .

{Glucanases} [2013-01]

C12N 9/2408

. . . . .

{acting on alpha -1,4-glucosidic bonds} [2013-01]

C12N 9/2411

. . . . . .

{Amylases} [2013-01]

C12N 9/2414

. . . . . . .

{Alpha-amylase (3.2.1.1.)} [2013-01]

C12N 9/2417

. . . . . . . .

{from microbiological source} [2013-01]

C12N 9/242

. . . . . . . . .

{Fungal source} [2013-01]

C12N 9/2422

. . . . . . . .

{from plant source} [2013-01]

C12N 9/2425

. . . . . . .

{Beta-amylase (3.2.1.2)} [2013-01]

C12N 9/2428

. . . . . . .

{Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase} [2013-01]

C12N 9/2431

. . . . . .

{Beta-fructofuranosidase (3.2.1.26), i.e. invertase} [2013-01]

C12N 9/2434

. . . . .

{acting on beta-1,4-glucosidic bonds} [2013-01]

C12N 9/2437

. . . . . .

{Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)} [2013-01]

C12N 9/244

. . . . . .

{Endo-1,3(4)-beta-glucanase (3.2.1.6)} [2013-01]

C12N 9/2442

. . . . . .

{Chitinase (3.2.1.14)} [2013-01]

C12N 9/2445

. . . . . .

{Beta-glucosidase (3.2.1.21)} [2013-01]

C12N 9/2448

. . . . . .

{Licheninase (3.2.1.73)} [2013-01]

C12N 9/2451

. . . . .

{acting on alpha-1,6-glucosidic bonds} [2013-01]

C12N 9/2454

. . . . . .

{Dextranase (3.2.1.11)} [2013-01]

C12N 9/2457

. . . . . .

{Pullulanase (3.2.1.41)} [2013-01]

C12N 9/246

. . . . . .

{Isoamylase (3.2.1.68)} [2013-01]

C12N 9/2462

. . . .

{Lysozyme (3.2.1.17)} [2013-01]

C12N 9/2465

. . . .

{acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)} [2013-01]

C12N 9/2468

. . . .

{acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)} [2013-01]

C12N 9/2471

. . . . .

{Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase} [2013-01]

C12N 9/2474

. . . .

{Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase} [2017-01]

C12N 9/2477

. . . .

{Hemicellulases not provided in a preceding group} [2013-01]

C12N 9/248

. . . . .

{Xylanases} [2013-01]

C12N 9/2482

. . . . . .

{Endo-1,4-beta-xylanase (3.2.1.8)} [2013-01]

C12N 9/2485

. . . . . .

{Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase} [2013-01]

C12N 9/2488

. . . . .

{Mannanases} [2013-01]

C12N 9/2491

. . . . . .

{Beta-mannosidase (3.2.1.25), i.e. mannanase} [2013-01]

C12N 9/2494

. . . . . .

{Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase} [2013-01]

C12N 9/2497

. . .

{hydrolysing N- glycosyl compounds (3.2.2)} [2013-01]

C12N 9/48

. .

acting on peptide bonds (3.4) [2013-01]

C12N 9/485

. . .

{Exopeptidases (3.4.11-3.4.19)} [2013-01]

C12N 9/50

. . .

Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)} [2021-08]

C12N 9/503

. . . .

{derived from viruses} [2013-01]

C12N 9/506

. . . . .

{derived from RNA viruses} [2013-01]

C12N 9/52

. . . .

derived from bacteria {or Archaea} [2021-08]

NOTE

{In this group, Archaea, formerly known as Archaebacteria, are classified with bacteria.}

C12N 9/54

. . . . .

bacteria being Bacillus [2013-01]

C12N 9/58

. . . .

derived from fungi [2013-01]

C12N 9/60

. . . . .

from yeast [2013-01]

C12N 9/62

. . . . .

from Aspergillus [2013-01]

C12N 9/63

. . . .

{derived from plants} [2013-01]

C12N 9/64

. . . .

derived from animal tissue [2013-01]

C12N 9/6402

. . . . .

{from non-mammals} [2013-01]

C12N 9/6405

. . . . . .

{not being snakes} [2013-01]

C12N 9/6408

. . . . . . .

{Serine endopeptidases (3.4.21)} [2013-01]

C12N 9/641

. . . . . . .

{Cysteine endopeptidases (3.4.22)} [2013-01]

C12N 9/6413

. . . . . . .

{Aspartic endopeptidases (3.4.23)} [2013-01]

C12N 9/6416

. . . . . . .

{Metalloendopeptidases (3.4.24)} [2013-01]

C12N 9/6418

. . . . . .

{from snakes} [2013-01]

C12N 9/6421

. . . . .

{from mammals} [2013-01]

C12N 9/6424

. . . . . .

{Serine endopeptidases (3.4.21)} [2013-01]

C12N 9/6427

. . . . . . .

{Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)} [2013-01]

C12N 9/6429

. . . . . . .

{Thrombin (3.4.21.5)} [2013-01]

C12N 9/6432

. . . . . . .

{Coagulation factor Xa (3.4.21.6)} [2013-01]

C12N 9/6435

. . . . . . .

{Plasmin (3.4.21.7), i.e. fibrinolysin} [2013-01]

C12N 9/6437

. . . . . . .

{Coagulation factor VIIa (3.4.21.21)} [2013-01]

C12N 9/644

. . . . . . .

{Coagulation factor IXa (3.4.21.22)} [2013-01]

C12N 9/6443

. . . . . . .

{Coagulation factor XIa (3.4.21.27)} [2013-01]

C12N 9/6445

. . . . . . .

{Kallikreins (3.4.21.34; 3.4.21.35)} [2013-01]

C12N 9/6448

. . . . . . .

{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)} [2013-01]

C12N 9/6451

. . . . . . .

{Coagulation factor XIIa (3.4.21.38)} [2013-01]

C12N 9/6454

. . . . . . .

{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases} [2013-01]

C12N 9/6456

. . . . . . .

{Plasminogen activators} [2013-01]

C12N 9/6459

. . . . . . . .

{t-plasminogen activator (3.4.21.68), i.e. tPA} [2013-01]

C12N 9/6462

. . . . . . . .

{u-Plasminogen activator (3.4.21.73), i.e. urokinase} [2013-01]

C12N 9/6464

. . . . . . .

{Protein C (3.4.21.69)} [2013-01]

C12N 9/6467

. . . . . . .

{Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)} [2017-01]

C12N 9/647

. . . . . . .

{Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups} [2013-01]

C12N 9/6472

. . . . . .

{Cysteine endopeptidases (3.4.22)} [2013-01]

C12N 9/6475

. . . . . . .

{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)} [2013-01]

C12N 9/6478

. . . . . .

{Aspartic endopeptidases (3.4.23)} [2013-01]

C12N 9/6481

. . . . . . .

{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)} [2013-01]

C12N 9/6483

. . . . . . .

{Chymosin (3.4.23.4), i.e. rennin} [2013-01]

C12N 9/6486

. . . . . . .

{Renin (3.4.23.15)} [2013-01]

C12N 9/6489

. . . . . .

{Metalloendopeptidases (3.4.24)} [2013-01]

C12N 9/6491

. . . . . . .

{Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)} [2017-08]

C12N 9/6494

. . . . . . .

{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11} [2013-01]

C12N 9/6497

. . . . . . .

{Endothelin-converting enzyme (3.4.24.71)} [2013-01]

C12N 9/78

. .

acting on carbon to nitrogen bonds other than peptide bonds (3.5) [2013-01]

C12N 9/80

. . .

acting on amide bonds in linear amides {(3.5.1)} [2013-01]

C12N 9/82

. . . .

Asparaginase {(3.5.1.1)} [2013-01]

C12N 9/84

. . . .

Penicillin amidase {(3.5.1.11)} [2013-01]

C12N 9/86

. . .

acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)} [2013-01]

C12N 9/88

Lyases (4.) [2013-01]

C12N 9/90

Isomerases (5.) [2013-01]

C12N 9/92

. .

Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)} [2013-01]

C12N 9/93

{Ligases (6)} [2013-01]

C12N 9/94

Pancreatin [2013-01]

C12N 9/96

Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates [2013-01]

C12N 9/98

Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence) [2013-01]

C12N 9/99

Enzyme inactivation by chemical treatment [2013-01]

C12N 11/00

Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof [2013-01]

C12N 11/02

Enzymes or microbial cells immobilised on or in an organic carrier [2020-01]

C12N 11/04

. .

entrapped within the carrier, e.g. gel or hollow fibres [2020-01]

C12N 11/06

. .

attached to the carrier via a bridging agent [2013-01]

C12N 11/08

. .

the carrier being a synthetic polymer [2022-05]

C12N 11/082

. . .

obtained by reactions only involving carbon-to-carbon unsaturated bonds [2022-05]

C12N 11/084

. . . .

Polymers containing vinyl alcohol units [2020-01]

C12N 11/087

. . . .

Acrylic polymers [2020-01]

C12N 11/089

. . .

obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [2022-05]

C12N 11/091

. . . .

Phenol resins; Amino resins [2020-01]

C12N 11/093

. . . .

Polyurethanes [2020-01]

C12N 11/096

. . . .

Polyesters; Polyamides [2020-01]

C12N 11/098

. . .

formed in the presence of the enzymes or microbial cells [2022-05]

C12N 11/10

. .

the carrier being a carbohydrate [2020-01]

C12N 11/12

. . .

Cellulose or derivatives thereof [2017-08]

C12N 11/14

Enzymes or microbial cells immobilised on or in an inorganic carrier [2020-01]

C12N 11/16

Enzymes or microbial cells immobilised on or in a biological cell [2020-01]

C12N 11/18

Multi-enzyme systems [2013-01]

C12N 13/00

Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves [2017-08]

C12N 15/00

Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00) [2017-08]

C12N 15/01

Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor [2013-01]

C12N 15/02

Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M)} [2013-01]

C12N 15/03

. .

Bacteria [2013-01]

C12N 15/04

. .

Fungi [2013-01]

C12N 15/09

Recombinant DNA-technology [2013-01]

C12N 15/10

. .

Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34) [2022-05]

NOTE

{In groups C12N 15/10 - C12N 15/1096, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N}.

C12N 15/1003

. . .

{Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor} [2013-01]

C12N 15/1006

. . . .

{by means of a solid support carrier, e.g. particles, polymers} [2013-01]

C12N 15/101

. . . . .

{by chromatography, e.g. electrophoresis, ion-exchange, reverse phase} [2013-01]

C12N 15/1013

. . . . .

{by using magnetic beads} [2013-01]

C12N 15/1017

. . . .

{by filtration, e.g. using filters, frits, membranes} [2013-01]

C12N 15/102

. . .

{Mutagenizing nucleic acids} [2013-01]

C12N 15/1024

. . . .

{In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair} [2013-01]

C12N 15/1027

. . . .

{by DNA shuffling, e.g. RSR, STEP, RPR} [2013-01]

C12N 15/1031

. . . .

{mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR} [2013-01]

C12N 15/1034

. . .

{Isolating an individual clone by screening libraries} [2013-01]

C12N 15/1037

. . . .

{Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display} [2013-01]

C12N 15/1041

. . . .

{Ribosome/Polysome display, e.g. SPERT, ARM} [2013-01]

C12N 15/1044

. . . .

{Preparation or screening of libraries displayed on scaffold proteins} [2016-11]

C12N 15/1048

. . . .

{SELEX} [2013-01]

C12N 15/1051

. . . .

{Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors} [2013-01]

C12N 15/1055

. . . .

{Protein x Protein interaction, e.g. two hybrid selection} [2013-01]

C12N 15/1058

. . . .

{Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms} [2013-01]

C12N 15/1062

. . . .

{mRNA-Display, e.g. polypeptide and encoding template are connected covalently} [2013-01]

C12N 15/1065

. . . .

{Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags} [2013-01]

C12N 15/1068

. . . .

{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis} [2013-01]

C12N 15/1072

. . . .

{Differential gene expression library synthesis, e.g. subtracted libraries, differential screening} [2013-01]

C12N 15/1075

. . . .

{by coupling phenotype to genotype, not provided for in other groups of this subclass} [2013-01]

C12N 15/1079

. . . .

{Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)} [2013-01]

C12N 15/1082

. . . .

{Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors} [2013-01]

C12N 15/1086

. . . .

{Preparation or screening of expression libraries, e.g. reporter assays} [2013-01]

C12N 15/1089

. . . .

{Design, preparation, screening or analysis of libraries using computer algorithms} [2013-01]

C12N 15/1093

. . . .

{General methods of preparing gene libraries, not provided for in other subgroups} [2013-01]

C12N 15/1096

. . .

{cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR} [2013-01]

C12N 15/11

. .

DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00); {Non-coding nucleic acids having a biological activity} [2016-05]

NOTE

- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N 15/11 - C12N 15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N 2303/00 ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N 15/111

C12N 15/111

. . .

{General methods applicable to biologically active non-coding nucleic acids} [2013-01]

C12N 15/113

. . .

Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)} [2017-01]

C12N 15/1131

. . . .

{against viruses} [2013-01]

C12N 15/1132

. . . . .

{against retroviridae, e.g. HIV} [2013-01]

C12N 15/1133

. . . . .

{against herpetoviridae, e.g. HSV} [2013-01]

C12N 15/1135

. . . .

{against oncogenes or tumor suppressor genes} [2013-01]

C12N 15/1136

. . . .

{against growth factors, growth regulators, cytokines, lymphokines or hormones} [2013-01]

C12N 15/1137

. . . .

{against enzymes (viral enzymes C12N 15/1131; receptors C12N 15/1138)} [2013-01]

C12N 15/1138

. . . .

{against receptors or cell surface proteins} [2013-01]

C12N 15/115

. . .

Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} [2017-08]

NOTE

Aptamers fused to compounds which are already classified in groups C12N 15/11 - C12N 15/117, are classified with the corresponding compound

C12N 15/117

. . .

Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs [2013-01]

C12N 15/52

. . .

Genes encoding for enzymes or proenzymes [2013-01]

NOTE

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

C12N 15/62

. . .

DNA sequences coding for fusion proteins [2013-01]

NOTE

In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.

C12N 15/625

. . . .

{containing a sequence coding for a signal sequence} [2013-01]

C12N 15/63

. .

Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression [2013-01]

C12N 15/635

. . .

{Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline} [2013-01]

C12N 15/64

. . .

General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host [2022-05]

NOTE

{In the group C12N 15/64, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N}

C12N 15/65

. . .

using markers (enzymes used as markers C12N 15/52) [2022-05]

NOTE

{In the group C12N 15/65, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N}

C12N 15/66

. . .

General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease [2022-05]

NOTES

In this group, the following expression is used with the meaning indicated:
- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.
{In the group C12N 15/66, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N}

C12N 15/67

. . .

General methods for enhancing the expression [2013-01]

C12N 15/68

. . . .

Stabilisation of the vector [2013-01]

C12N 15/69

. . . .

Increasing the copy number of the vector [2013-01]

C12N 15/70

. . .

Vectors or expression systems specially adapted for E. coli [2013-01]

NOTES

This group covers the use of E. coli as host.
Shuttle vectors also replicating in E. coli are classified according to the other host.

C12N 15/71

. . . .

Expression systems using regulatory sequences derived from the trp-operon [2013-01]

C12N 15/72

. . . .

Expression systems using regulatory sequences derived from the lac-operon [2013-01]

C12N 15/73

. . . .

Expression systems using phage (lambda) regulatory sequences [2013-01]

C12N 15/74

. . .

Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora [2013-01]

NOTE

This group covers the use of prokaryotes as hosts.

C12N 15/743

. . . .

{for Agrobacterium; Rhizobium; Bradyrhizobium} [2013-01]

C12N 15/746

. . . .

{for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)} [2013-01]

C12N 15/75

. . . .

for Bacillus [2013-01]

C12N 15/76

. . . .

for Actinomyces; for Streptomyces [2013-01]

C12N 15/77

. . . .

for Corynebacterium; for Brevibacterium [2013-01]

C12N 15/78

. . . .

for Pseudomonas [2013-01]

C12N 15/79

. . .

Vectors or expression systems specially adapted for eukaryotic hosts [2013-01]

NOTE

This group covers the use of eukaryotes as hosts.

C12N 15/80

. . . .

for fungi [2013-01]

C12N 15/81

. . . . .

for yeasts [2013-01]

C12N 15/815

. . . . . .

{for yeasts other than Saccharomyces} [2013-01]

C12N 15/82

. . . .

for plant cells {, e.g. plant artificial chromosomes (PACs)} [2017-08]

WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

C12N 15/8201

. . . . .

{Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation} [2013-01]

C12N 15/8202

. . . . . .

{by biological means, e.g. cell mediated or natural vector} [2013-01]

C12N 15/8203

. . . . . . .

{Virus mediated transformation} [2013-01]

C12N 15/8205

. . . . . . .

{Agrobacterium mediated transformation} [2013-01]

C12N 15/8206

. . . . . .

{by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated} [2013-01]

C12N 15/8207

. . . . . . .

{by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers} [2013-01]

C12N 15/8209

. . . . . .

{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers} [2013-01]

NOTE

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209

C12N 15/821

. . . . . . .

{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers} [2015-07]

C12N 15/8212

. . . . . . . .

{Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid} [2015-07]

C12N 15/8213

. . . . . .

{Targeted insertion of genes into the plant genome by homologous recombination} [2013-01]

C12N 15/8214

. . . . . .

{Plastid transformation} [2013-01]

C12N 15/8216

. . . . .

{Methods for controlling, regulating or enhancing expression of transgenes in plant cells} [2013-01]

C12N 15/8217

. . . . . .

{Gene switch} [2015-07]

C12N 15/8218

. . . . . .

{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]} [2015-07]

C12N 15/822

. . . . . .

{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression} [2015-07]

C12N 15/8221

. . . . . .

{Transit peptides} [2015-07]

C12N 15/8222

. . . . . .

{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation} [2013-01]

C12N 15/8223

. . . . . . .

{Vegetative tissue-specific promoters} [2015-07]

C12N 15/8225

. . . . . . . .

{Leaf-specific, e.g. including petioles, stomata} [2015-07]

C12N 15/8226

. . . . . . . .

{Stem-specific, e.g. including tubers, beets} [2015-07]

C12N 15/8227

. . . . . . . .

{Root-specific} [2015-07]

C12N 15/8229

. . . . . . . .

{Meristem-specific, e.g. nodal, apical} [2015-07]

C12N 15/823

. . . . . . .

{Reproductive tissue-specific promoters} [2015-07]

C12N 15/8231

. . . . . . . .

{Male-specific, e.g. anther, tapetum, pollen} [2015-07]

C12N 15/8233

. . . . . . . .

{Female-specific, e.g. pistil, ovule} [2015-07]

C12N 15/8234

. . . . . . . .

{Seed-specific, e.g. embryo, endosperm} [2015-07]

C12N 15/8235

. . . . . . . .

{Fruit-specific} [2015-07]

C12N 15/8237

. . . . . .

{Externally regulated expression systems} [2013-01]

C12N 15/8238

. . . . . . .

{chemically inducible, e.g. tetracycline} [2015-07]

C12N 15/8239

. . . . . . .

{pathogen inducible} [2015-07]

C12N 15/8241

. . . . .

{Phenotypically and genetically modified plants via recombinant DNA technology} [2013-01]

C12N 15/8242

. . . . . .

{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits} [2013-01]

C12N 15/8243

. . . . . . .

{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine} [2013-01]

C12N 15/8245

. . . . . . . .

{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis} [2013-01]

C12N 15/8246

. . . . . . . . .

{Non-starch polysaccharides, e.g. cellulose, fructans, levans} [2015-07]

C12N 15/8247

. . . . . . . .

{involving modified lipid metabolism, e.g. seed oil composition} [2013-01]

C12N 15/8249

. . . . . . . .

{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life} [2013-01]

C12N 15/825

. . . . . . . .

{involving pigment biosynthesis} [2013-01]

NOTE

Transgenic plants with altered flower morphology are also classified in this group

C12N 15/8251

. . . . . . . .

{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis} [2013-01]

C12N 15/8253

. . . . . . . . .

{Methionine or cysteine} [2015-07]

C12N 15/8254

. . . . . . . . .

{Tryptophan or lysine} [2015-07]

C12N 15/8255

. . . . . . . .

{involving lignin biosynthesis} [2015-07]

C12N 15/8257

. . . . . . .

{for the production of primary gene products, e.g. pharmaceutical products, interferon} [2013-01]

C12N 15/8258

. . . . . . . .

{for the production of oral vaccines (antigens) or immunoglobulins} [2013-01]

C12N 15/8259

. . . . . . .

{Phytoremediation} [2015-07]

C12N 15/8261

. . . . . .

{with agronomic (input) traits, e.g. crop yield} [2013-01]

C12N 15/8262

. . . . . . .

{involving plant development} [2020-05]

C12N 15/8263

. . . . . . . .

{Ablation; Apoptosis} [2015-07]

C12N 15/8265

. . . . . . . .

{Transgene containment, e.g. gene dispersal} [2015-07]

C12N 15/8266

. . . . . . . .

{Abscission; Dehiscence; Senescence} [2015-07]

C12N 15/8267

. . . . . . . .

{Seed dormancy, germination or sprouting} [2015-07]

C12N 15/8269

. . . . . . . .

{Photosynthesis} [2015-07]

C12N 15/827

. . . . . . . .

{Flower development or morphology, e.g. flowering promoting factor [FPF]} [2015-07]

C12N 15/8271

. . . . . . .

{for stress resistance, e.g. heavy metal resistance} [2013-01]

C12N 15/8273

. . . . . . . .

{for drought, cold, salt resistance} [2015-07]

C12N 15/8274

. . . . . . . .

{for herbicide resistance} [2013-01]

C12N 15/8275

. . . . . . . . .

{Glyphosate} [2015-07]

C12N 15/8277

. . . . . . . . .

{Phosphinotricin} [2015-07]

C12N 15/8278

. . . . . . . . .

{Sulfonylurea} [2015-07]

C12N 15/8279

. . . . . . . .

{for biotic stress resistance, pathogen resistance, disease resistance} [2013-01]

C12N 15/8281

. . . . . . . . .

{for bacterial resistance} [2015-07]

C12N 15/8282

. . . . . . . . .

{for fungal resistance} [2015-07]

C12N 15/8283

. . . . . . . . .

{for virus resistance} [2013-01]

C12N 15/8285

. . . . . . . . .

{for nematode resistance} [2013-01]

C12N 15/8286

. . . . . . . . .

{for insect resistance} [2013-01]

C12N 15/8287

. . . . . . .

{for fertility modification, e.g. apomixis} [2013-01]

C12N 15/8289

. . . . . . . .

{Male sterility} [2015-07]

C12N 15/829

. . . . . . . .

{Female sterility} [2015-07]

C12N 15/8291

. . . . . . .

{Hormone-influenced development} [2015-07]

C12N 15/8293

. . . . . . . .

{Abscisic acid [ABA]} [2015-07]

C12N 15/8294

. . . . . . . .

{Auxins} [2015-07]

C12N 15/8295

. . . . . . . .

{Cytokinins} [2015-07]

C12N 15/8297

. . . . . . . .

{Gibberellins; GA3} [2015-07]

C12N 15/8298

. . . . . . . .

{Brassinosteroids} [2015-07]

C12N 15/85

. . . .

for animal cells [2013-01]

C12N 15/8509

. . . . .

{for producing genetically modified animals, e.g. transgenic} [2018-01]

NOTE

Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00

C12N 2015/8518

. . . . . .

{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles} [2013-01]

C12N 2015/8527

. . . . . .

{for producing animal models, e.g. for tests or diseases} [2013-01]

C12N 2015/8536

. . . . . . .

{Animal models for genetic diseases} [2013-01]

C12N 2015/8545

. . . . . . . .

{for Alzheimer''s disease} [2013-01]

C12N 2015/8554

. . . . . . . . .

{Invertebrates models for Alzheimer''s disease} [2013-01]

C12N 2015/8563

. . . . . . . .

{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus} [2013-01]

C12N 2015/8572

. . . . . . .

{Animal models for proliferative diseases, e.g. comprising an oncogene} [2013-01]

C12N 2015/8581

. . . . . . .

{Animal models for infectious diseases, e.g. AIDS} [2013-01]

C12N 2015/859

. . . . . . .

{Animal models comprising reporter system for screening tests} [2013-01]

C12N 15/86

. . . . .

Viral vectors [2013-01]

WARNING

From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00

C12N 15/861

. . . . . .

Adenoviral vectors [2013-01]

C12N 15/8613

. . . . . . .

{Chimaeric vector systems comprising heterologous sequences for production of another viral vector} [2013-01]

C12N 15/8616

. . . . . . .

{Special methods for targeting systems} [2013-01]

C12N 15/863

. . . . . .

Poxviral vectors, {e.g. entomopoxvirus} [2013-01]

C12N 15/8633

. . . . . . .

{Avian poxviral vectors} [2013-01]

C12N 15/8636

. . . . . . .

{Vaccina virus vectors} [2013-01]

C12N 15/864

. . . . . .

Parvoviral vectors {, e.g. parvovirus, densovirus} [2017-08]

C12N 15/8645

. . . . . . .

{Adeno-associated virus} [2013-01]

C12N 15/866

. . . . . .

Baculoviral vectors [2013-01]

C12N 15/867

. . . . . .

Retroviral vectors [2013-01]

C12N 15/8673

. . . . . . .

{Special methods for packaging systems} [2013-01]

C12N 15/8676

. . . . . . .

{Special methods for targeting systems} [2013-01]

C12N 15/869

. . . . . .

Herpesviral vectors [2013-01]

C12N 15/8695

. . . . . . .

{Herpes simplex virus-based vectors} [2013-01]

C12N 15/87

. .

Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation [2013-01]

C12N 15/873

. . .

Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos [2013-01]

C12N 15/877

. . . .

Techniques for producing new mammalian cloned embryos [2017-02]

C12N 15/8771

. . . . .

{Bovine embryos} [2013-01]

C12N 15/8772

. . . . .

{Caprine embryos} [2013-01]

C12N 15/8773

. . . . .

{Ovine embryos} [2013-01]

C12N 15/8775

. . . . .

{Murine embryos} [2013-01]

C12N 15/8776

. . . . .

{Primate embryos} [2013-01]

C12N 15/8777

. . . . .

{Rabbit embryos} [2013-01]

C12N 15/8778

. . . . .

{Swine embryos} [2013-01]

C12N 15/88

. . .

using microencapsulation, e.g. using {amphiphile} liposome vesicle [2017-08]

C12N 15/89

. . .

using microinjection [2017-08]

C12N 15/895

. . . .

{using biolistic methods} [2013-01]

C12N 15/90

. . .

Stable introduction of foreign DNA into chromosome [2013-01]

C12N 15/902

. . . .

{using homologous recombination} [2013-01]

C12N 15/905

. . . . .

{in yeast} [2018-01]

C12N 15/907

. . . . .

{in mammalian cells} [2013-01]

C12N 2303/00

Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids [2013-01]

NOTE

Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111

C12N 2310/00

Structure or type of the nucleic acid [2022-05]

NOTE

In groups C12N 2310/00 - C12N 2310/533, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N.

C12N 2310/10

Type of nucleic acid [2013-01]

C12N 2310/11

. .

Antisense [2013-01]

C12N 2310/111

. . .

spanning the whole gene, or a large part of it [2013-01]

C12N 2310/113

. . .

targeting other non-coding nucleic acids, e.g. antagomirs [2013-01]

C12N 2310/12

. .

catalytic nucleic acids, e.g. ribozymes [2013-01]

C12N 2310/121

. . .

Hammerhead [2013-01]

C12N 2310/122

. . .

Hairpin [2013-01]

C12N 2310/123

. . .

Hepatitis delta [2013-01]

C12N 2310/124

. . .

based on group I or II introns [2013-01]

C12N 2310/1241

. . . .

Tetrahymena [2013-01]

C12N 2310/126

. . .

involving RNAse P [2013-01]

C12N 2310/127

. . .

DNAzymes [2013-01]

C12N 2310/128

. . .

processing or releasing ribozyme [2013-01]

C12N 2310/13

. .

Decoys [2013-01]

C12N 2310/14

. .

interfering N.A. [2013-01]

C12N 2310/141

. . .

MicroRNAs, miRNAs [2013-01]

C12N 2310/15

. .

Nucleic acids forming more than 2 strands, e.g. TFOs [2013-01]

C12N 2310/151

. . .

more than 3 strands, e.g. tetrads, H-DNA [2013-01]

C12N 2310/152

. . .

on a single-stranded target, e.g. fold-back TFOs [2013-01]

C12N 2310/153

. . .

with the aid of a protein, e.g. recombinase [2013-01]

C12N 2310/16

. .

Aptamers [2013-01]

C12N 2310/17

. .

Immunomodulatory nucleic acids [2013-01]

C12N 2310/18

. .

acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17) [2013-01]

C12N 2310/20

. .

involving clustered regularly interspaced short palindromic repeats [CRISPRs] [2017-05]

C12N 2310/30

Chemical structure [2013-01]

C12N 2310/31

. .

of the backbone [2013-01]

C12N 2310/311

. . .

Phosphotriesters [2013-01]

C12N 2310/312

. . .

Phosphonates [2013-01]

C12N 2310/3125

. . . .

Methylphosphonates [2013-01]

C12N 2310/313

. . .

Phosphorodithioates [2013-01]

C12N 2310/314

. . .

Phosphoramidates [2013-01]

C12N 2310/3145

. . . .

with the nitrogen in 3' or 5'-position [2013-01]

C12N 2310/315

. . .

Phosphorothioates [2013-01]

C12N 2310/316

. . .

Phosphonothioates [2013-01]

C12N 2310/317

. . .

with an inverted bond, e.g. a cap structure [2013-01]

C12N 2310/318

. . .

where the PO2 is completely replaced, e.g. MMI or formacetal [2013-01]

C12N 2310/3181

. . . .

Peptide nucleic acid, PNA [2013-01]

C12N 2310/3183

. . . .

Diol linkers, e.g. glycols or propanediols [2013-01]

C12N 2310/319

. . .

linked by 2'-5' linkages, i.e. having a free 3'-position [2013-01]

C12N 2310/32

. .

of the sugar [2013-01]

C12N 2310/321

. . .

2'-O-R Modification [2013-01]

C12N 2310/322

. . .

2'-R Modification [2013-01]

C12N 2310/323

. . .

modified ring structure [2013-01]

C12N 2310/3231

. . . .

having an additional ring, e.g. LNA, ENA [2013-01]

C12N 2310/3233

. . . .

Morpholino-type ring [2013-01]

C12N 2310/3235

. . . .

having the O of the ribose replaced by another atom [2013-01]

C12N 2310/33

. .

of the base [2013-01]

C12N 2310/331

. . .

Universal or degenerate base [2013-01]

C12N 2310/332

. . .

Abasic residue [2013-01]

C12N 2310/333

. . .

Modified A [2013-01]

C12N 2310/334

. . .

Modified C [2013-01]

C12N 2310/3341

. . . .

5-Methylcytosine [2013-01]

C12N 2310/335

. . .

Modified T or U [2013-01]

C12N 2310/336

. . .

Modified G [2013-01]

C12N 2310/337

. . .

in alpha-anomeric form [2013-01]

C12N 2310/34

. .

Spatial arrangement of the modifications [2013-01]

C12N 2310/341

. . .

Gapmers, i.e. of the type ===---=== [2013-01]

C12N 2310/342

. . .

Hemimers, i.e. of the type ====---- [2013-01]

C12N 2310/343

. . .

having patterns, e.g. ==--==--==-- [2013-01]

C12N 2310/344

. . .

Position-specific modifications, e.g. on every purine, at the 3'-end [2013-01]

C12N 2310/345

. . .

having at least two different backbone modifications [2013-01]

C12N 2310/346

. . .

having a combination of backbone and sugar modifications [2013-01]

C12N 2310/35

. .

Nature of the modification [2013-01]

C12N 2310/351

. . .

Conjugate [2013-01]

C12N 2310/3511

. . . .

intercalating or cleaving agent [2013-01]

C12N 2310/3513

. . . .

Protein; Peptide [2013-01]

C12N 2310/3515

. . . .

Lipophilic moiety, e.g. cholesterol [2013-01]

C12N 2310/3517

. . . .

Marker; Tag [2013-01]

C12N 2310/3519

. . . .

Fusion with another nucleic acid [2013-01]

C12N 2310/352

. . .

linked to the nucleic acid via a carbon atom [2013-01]

C12N 2310/3521

. . . .

Methyl [2013-01]

C12N 2310/3523

. . . .

Allyl [2013-01]

C12N 2310/3525

. . . .

MOE, methoxyethoxy [2013-01]

C12N 2310/3527

. . . .

Other alkyl chain [2013-01]

C12N 2310/3529

. . . .

Aromatic substituent [2013-01]

C12N 2310/353

. . .

linked to the nucleic acid via an atom other than carbon [2013-01]

C12N 2310/3531

. . . .

Hydrogen [2016-11]

C12N 2310/3533

. . . .

Halogen [2016-11]

C12N 2310/3535

. . . .

Nitrogen [2016-11]

C12N 2310/50

Physical structure [2013-01]

C12N 2310/51

. .

in polymeric form, e.g. multimers, concatemers [2013-01]

C12N 2310/52

. .

branched [2013-01]

C12N 2310/53

. .

partially self-complementary or closed [2013-01]

C12N 2310/531

. . .

Stem-loop; Hairpin [2013-01]

C12N 2310/532

. . .

Closed or circular [2013-01]

C12N 2310/533

. . .

having a mismatch or nick in at least one of the strands [2013-01]

C12N 2320/00

Applications; Uses [2013-01]

C12N 2320/10

in screening processes [2013-01]

C12N 2320/11

. .

for the determination of target sites, i.e. of active nucleic acids [2013-01]

C12N 2320/12

. .

in functional genomics, i.e. for the determination of gene function [2013-01]

C12N 2320/13

. .

in a process of directed evolution, e.g. SELEX, acquiring a new function [2013-01]

C12N 2320/30

Special therapeutic applications [2013-01]

C12N 2320/31

. .

Combination therapy [2013-01]

C12N 2320/32

. .

Special delivery means, e.g. tissue-specific [2013-01]

C12N 2320/33

. .

Alteration of splicing [2013-01]

C12N 2320/34

. .

Allele or polymorphism specific uses [2013-01]

C12N 2320/35

. .

based on a specific dosage / administration regimen [2013-01]

C12N 2320/50

Methods for regulating/modulating their activity [2013-01]

C12N 2320/51

. .

modulating the chemical stability, e.g. nuclease-resistance [2013-01]

C12N 2320/52

. .

modulating the physical stability, e.g. GC-content [2013-01]

C12N 2320/53

. .

reducing unwanted side-effects [2013-01]

C12N 2330/00

Production [2013-01]

C12N 2330/10

naturally occurring [2013-01]

C12N 2330/30

chemically synthesised [2013-01]

C12N 2330/31

. .

Libraries, arrays [2013-01]

C12N 2330/50

Biochemical production, i.e. in a transformed host cell [2013-01]

C12N 2330/51

. .

Specially adapted vectors [2013-01]

C12N 2500/00

Specific components of cell culture medium [2013-01]

C12N 2500/02

Atmosphere, e.g. low oxygen conditions [2013-01]

C12N 2500/05

Inorganic components [2013-01]

C12N 2500/10

. .

Metals; Metal chelators (cobalamine C12N 2500/38) [2013-01]

C12N 2500/12

. . .

Light metals, i.e. alkali, alkaline earth, Be, Al, Mg [2013-01]

C12N 2500/14

. . . .

Calcium; Ca chelators; Calcitonin [2013-01]

C12N 2500/16

. . . .

Magnesium; Mg chelators [2013-01]

C12N 2500/20

. . .

Transition metals [2013-01]

C12N 2500/22

. . . .

Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33) [2013-01]

C12N 2500/24

. . . .

Iron; Fe chelators; Transferrin [2013-01]

C12N 2500/25

. . . . .

Insulin-transferrin; Insulin-transferrin-selenium [2013-01]

C12N 2500/30

Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24) [2013-01]

C12N 2500/32

. .

Amino acids [2013-01]

C12N 2500/33

. . .

other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine [2013-01]

C12N 2500/34

. .

Sugars [2013-01]

C12N 2500/35

. .

Polyols, e.g. glycerin, inositol [2013-01]

C12N 2500/36

. .

Lipids [2013-01]

C12N 2500/38

. .

Vitamins [2013-01]

C12N 2500/40

. .

Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplasic drugs C12N 2501/06) [2013-01]

C12N 2500/42

. .

Organic phosphate, e.g. beta glycerophosphate [2013-01]

C12N 2500/44

. .

Thiols, e.g. mercaptoethanol [2013-01]

C12N 2500/46

. .

Amines, e.g. putrescine [2013-01]

C12N 2500/50

Soluble polymers, e.g. polyethyleneglycol [PEG] [2013-01]

C12N 2500/60

Buffer, e.g. pH regulation, osmotic pressure [2013-01]

C12N 2500/62

. .

DMSO [2013-01]

C12N 2500/70

Undefined extracts (conditioned medium C12N 2502/00) [2013-01]

C12N 2500/72

. .

from bacteria [2013-01]

C12N 2500/74

. .

from fungi, e.g. yeasts [2013-01]

C12N 2500/76

. .

from plants [2013-01]

C12N 2500/78

. .

from protozoa [2013-01]

C12N 2500/80

. .

from animals [2013-01]

C12N 2500/82

. . .

from invertebrates [2013-01]

C12N 2500/84

. . .

from mammals [2013-01]

C12N 2500/90

Serum-free medium, which may still contain naturally-sourced components [2013-01]

C12N 2500/92

. .

Medium free of human- or animal-derived components [2013-01]

C12N 2500/95

. .

Protein-free medium and culture conditions [2013-01]

C12N 2500/98

Xeno-free medium and culture conditions [2013-01]

C12N 2500/99

Serum-free medium [2016-05]

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 2500/90 - C12N 2500/98

C12N 2501/00

Active agents used in cell culture processes, e.g. differentation [2013-01]

NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

C12N 2501/01

Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin [2013-01]

C12N 2501/02

Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes [2013-01]

C12N 2501/03

Compounds acting on the NO pathway, e.g. nitrososarginine [2013-01]

C12N 2501/04

Immunosuppressors, e.g. cyclosporin, tacrolimus [2013-01]

C12N 2501/05

Adjuvants [2013-01]

C12N 2501/051

. .

Lipid A (MPA, MPL) [2013-01]

C12N 2501/052

. .

Lipopolysaccharides [LPS] [2013-01]

C12N 2501/054

. .

Muramyle peptides [2013-01]

C12N 2501/056

. .

Immunostimulating oligonucleotides, e.g. CpG [2013-01]

C12N 2501/06

Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide [2013-01]

C12N 2501/065

Modulators of histone acetylation [2013-01]

C12N 2501/07

Heat shock proteins [2013-01]

C12N 2501/10

Growth factors [2013-01]

C12N 2501/105

. .

Insulin-like growth factors [IGF] [2013-01]

C12N 2501/11

. .

Epidermal growth factor [EGF] [2013-01]

C12N 2501/113

. .

Acidic fibroblast growth factor (aFGF, FGF-1) [2013-01]

C12N 2501/115

. .

Basic fibroblast growth factor (bFGF, FGF-2) [2013-01]

C12N 2501/117

. .

Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12) [2013-01]

C12N 2501/119

. .

Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 [2013-01]

C12N 2501/12

. .

Hepatocyte growth factor [HGF] [2013-01]

C12N 2501/125

. .

Stem cell factor [SCF], c-kit ligand [KL] [2013-01]

C12N 2501/13

. .

Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins [2013-01]

C12N 2501/135

. .

Platelet-derived growth factor [PDGF] [2013-01]

C12N 2501/14

. .

Erythropoietin [EPO] [2013-01]

C12N 2501/145

. .

Thrombopoietin [TPO] [2013-01]

C12N 2501/148

. .

Transforming growth factor alpha [TGF-a] [2013-01]

C12N 2501/15

. .

Transforming growth factor beta (TGF-β) [2017-08]

C12N 2501/155

. .

Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor [2013-01]

C12N 2501/16

. .

Activin; Inhibin; Mullerian inhibiting substance [2013-01]

C12N 2501/165

. .

Vascular endothelial growth factor [VEGF] [2013-01]

C12N 2501/17

. .

Angiopoietin [2013-01]

C12N 2501/175

. .

Cardiotrophin [2013-01]

C12N 2501/18

. .

Liver cell growth factor (LCGF, Gly-His-Lys) [2013-01]

C12N 2501/185

. .

Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL) [2013-01]

C12N 2501/19

. .

Growth and differentiation factors [GDF] [2013-01]

C12N 2501/195

. .

Heregulin, neu differentiation factor [2013-01]

C12N 2501/20

Cytokines; Chemokines [2013-01]

C12N 2501/21

. .

Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4 [2013-01]

C12N 2501/22

. .

Colony stimulating factors (G-CSF, GM-CSF) [2013-01]

C12N 2501/23

. .

Interleukins [IL] [2013-01]

C12N 2501/2301

. . .

Interleukin-1 (IL-1) [2013-01]

C12N 2501/2302

. . .

Interleukin-2 (IL-2) [2013-01]

C12N 2501/2303

. . .

Interleukin-3 (IL-3) [2013-01]

C12N 2501/2304

. . .

Interleukin-4 (IL-4) [2013-01]

C12N 2501/2305

. . .

Interleukin-5 (IL-5) [2013-01]

C12N 2501/2306

. . .

Interleukin-6 (IL-6) [2013-01]

C12N 2501/2307

. . .

Interleukin-7 (IL-7) [2013-01]

C12N 2501/2308

. . .

Interleukin-8 (IL-8) [2013-01]

C12N 2501/2309

. . .

Interleukin-9 (IL-9) [2013-01]

C12N 2501/231

. . .

Interleukin-10 (IL-10) [2013-01]

C12N 2501/2311

. . .

Interleukin-11 (IL-11) [2013-01]

C12N 2501/2312

. . .

Interleukin-12 (IL-12) [2013-01]

C12N 2501/2313

. . .

Interleukin-13 (IL-13) [2013-01]

C12N 2501/2314

. . .

Interleukin-14 (IL-14) [2013-01]

C12N 2501/2315

. . .

Interleukin-15 (IL-15) [2013-01]

C12N 2501/2316

. . .

Interleukin-16 (IL-16) [2013-01]

C12N 2501/2317

. . .

Interleukin-17 (IL-17) [2013-01]

C12N 2501/2318

. . .

Interleukin-18 (IL-18) [2013-01]

C12N 2501/2319

. . .

Interleukin-19 (IL-19) [2013-01]

C12N 2501/232

. . .

Interleukin-20 (IL-20) [2013-01]

C12N 2501/2321

. . .

Interleukin-21 (IL-21) [2013-01]

C12N 2501/2322

. . .

Interleukin-22 (IL-22) [2013-01]

C12N 2501/2323

. . .

Interleukin-23 (IL-23) [2013-01]

C12N 2501/2324

. . .

Interleukin-24 (IL-24) [2013-01]

C12N 2501/2325

. . .

Interleukin-25 (IL-25) [2013-01]

C12N 2501/2326

. . .

Interleukin-26 (IL-26) [2013-01]

C12N 2501/2327

. . .

Interleukin-27 (IL-27) [2013-01]

C12N 2501/2328

. . .

Interleukin-28 (IL-28) [2013-01]

C12N 2501/2329

. . .

Interleukin-29 (IL-29) [2013-01]

C12N 2501/233

. . .

Interleukin-30 (IL-30) [2013-01]

C12N 2501/2331

. . .

Interleukin-31 (IL-31) [2013-01]

C12N 2501/2332

. . .

Interleukin-32 (IL-32) [2013-01]

C12N 2501/2333

. . .

Interleukin-33 (IL-33) [2013-01]

C12N 2501/2334

. . .

Interleukin-34 (IL-34) [2013-01]

C12N 2501/2335

. . .

Interleukin-35 (IL-35) [2013-01]

C12N 2501/235

. . .

Leukemia inhibitory factor [LIF] [2013-01]

C12N 2501/237

. .

Oncostatin M [OSM] [2013-01]

C12N 2501/24

. .

Interferons [IFN] [2013-01]

C12N 2501/25

. .

Tumour necrosing factors [TNF] [2013-01]

C12N 2501/26

. .

Flt-3 ligand (CD135L, flk-2 ligand) [2013-01]

C12N 2501/30

Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85) [2013-01]

C12N 2501/305

. .

Growth hormone [GH], aka. somatotropin [2013-01]

C12N 2501/31

. .

Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins [2013-01]

C12N 2501/315

. .

Prolactin [2013-01]

C12N 2501/32

. .

Angiotensins [AT], angiotensinogen [2013-01]

C12N 2501/33

. .

Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105) [2013-01]

C12N 2501/335

. .

Glucagon; Glucagon-like peptide [GLP]; Exendin [2013-01]

C12N 2501/34

. .

Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin [2013-01]

C12N 2501/345

. .

Gastrin; Cholecystokinins [CCK] [2013-01]

C12N 2501/35

. .

Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP] [2013-01]

C12N 2501/355

. .

Leptin [2013-01]

C12N 2501/36

. .

Somatostatin [2013-01]

C12N 2501/365

. .

Endothelin [2013-01]

C12N 2501/37

. .

Parathyroid hormone [PTH] [2013-01]

C12N 2501/375

. .

Thyroid stimulating hormone [TSH] [2013-01]

C12N 2501/38

. .

with nuclear receptors [2013-01]

C12N 2501/385

. . .

of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] [2013-01]

C12N 2501/39

. . .

Steroid hormones [2013-01]

C12N 2501/392

. . . .

Sexual steroids [2013-01]

C12N 2501/395

. . .

Thyroid hormones [2013-01]

C12N 2501/40

Regulators of development [2013-01]

C12N 2501/405

. .

Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases [2013-01]

C12N 2501/41

. .

Hedgehog proteins; Cyclopamine (inhibitor) [2013-01]

C12N 2501/415

. .

Wnt; Frizzeled [2013-01]

C12N 2501/42

. .

Notch; Delta; Jagged; Serrate [2013-01]

C12N 2501/48

. .

Regulators of apoptosis [2013-01]

C12N 2501/50

Cell markers; Cell surface determinants [2013-01]

C12N 2501/505

. .

CD4; CD8 [2013-01]

C12N 2501/51

. .

B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) [2013-01]

C12N 2501/515

. .

CD3, T-cell receptor complex [2013-01]

C12N 2501/52

. .

CD40, CD40-ligand (CD154) [2013-01]

C12N 2501/53

. .

CD2 [2013-01]

C12N 2501/58

. .

Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) [2013-01]

C12N 2501/585

. .

Integrins [2013-01]

C12N 2501/59

. .

Lectins [2013-01]

C12N 2501/599

. .

with CD designations not provided for elsewhere [2013-01]

C12N 2501/60

Transcription factors [2013-01]

C12N 2501/602

. .

Sox-2 [2013-01]

C12N 2501/603

. .

Oct-3/4 [2013-01]

C12N 2501/604

. .

Klf-4 [2013-01]

C12N 2501/605

. .

Nanog [2013-01]

C12N 2501/606

. .

c-Myc [2013-01]

C12N 2501/608

. .

Lin28 [2013-01]

C12N 2501/65

MicroRNA [2017-08]

C12N 2501/70

Enzymes [2013-01]

C12N 2501/71

. .

Oxidoreductases (EC 1.) [2013-01]

C12N 2501/72

. .

Transferases (EC 2.) (acetylation of histones C12N 2501/065) [2013-01]

C12N 2501/724

. . .

Glycosyltransferases (EC 2.4.) [2013-01]

C12N 2501/727

. . .

Kinases (EC 2.7.) [2013-01]

C12N 2501/73

. .

Hydrolases (EC 3.) [2013-01]

C12N 2501/734

. . .

Proteases (EC 3.4.) [2013-01]

C12N 2501/80

Neurotransmitters; Neurohormones [2013-01]

C12N 2501/805

. .

Acetylcholine [2013-01]

C12N 2501/81

. .

Adrenaline [2013-01]

C12N 2501/815

. .

Dopamine [2013-01]

C12N 2501/82

. .

Histamine [2013-01]

C12N 2501/825

. .

Serotonine (5-HT); Melatonine [2013-01]

C12N 2501/83

. .

Tachykinins, e.g. substance P [2013-01]

C12N 2501/835

. .

Neuropeptide Y [NPY]; Peptide YY [PYY] [2013-01]

C12N 2501/84

. .

Excitatory amino acids [2013-01]

C12N 2501/845

. .

Gamma amino butyric acid [GABA] [2013-01]

C12N 2501/85

Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [2013-01]

C12N 2501/855

. .

Corticotropin [ACTH] [2013-01]

C12N 2501/86

. .

Melanocyte-stimulating hormone [MSH] [2013-01]

C12N 2501/90

Polysaccharides [2013-01]

C12N 2501/905

. .

Hyaluronic acid [2013-01]

C12N 2501/91

. .

Heparin [2013-01]

C12N 2501/998

Proteins not provided for elsewhere [2013-01]

NOTE

Classification by pathway does not apply.

C12N 2501/999

Small molecules not provided for elsewhere [2013-01]

NOTE

Classification by pathway does not apply.

C12N 2502/00

Coculture with; Conditioned medium produced by [2013-01]

C12N 2502/02

embryonic cells [2013-01]

C12N 2502/025

. .

extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly [2013-01]

C12N 2502/03

non-embryonic pluripotent stem cells [2013-01]

C12N 2502/04

germ cells [2013-01]

C12N 2502/07

endocrine cells [2013-01]

C12N 2502/072

. .

adrenal cells [2013-01]

C12N 2502/074

. .

pinealocytes [2013-01]

C12N 2502/076

. .

pituitary cells [2013-01]

C12N 2502/078

. .

thyroid, parathyroid cells [2013-01]

C12N 2502/08

cells of the nervous system [2013-01]

C12N 2502/081

. .

neurons [2013-01]

C12N 2502/083

. .

sensory transducers [2013-01]

C12N 2502/085

. .

eye cells [2013-01]

C12N 2502/086

. .

glial cells [2013-01]

C12N 2502/088

. .

neural stem cells [2013-01]

C12N 2502/09

epidermal cells, skin cells, oral mucosa cells [2013-01]

C12N 2502/091

. .

melanocytes [2013-01]

C12N 2502/092

. .

hair cells [2013-01]

C12N 2502/094

. .

keratinocytes [2013-01]

C12N 2502/095

. .

mammary cells [2013-01]

C12N 2502/097

. .

oral mucosa cells [2013-01]

C12N 2502/098

. .

cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013-01]

C12N 2502/11

blood or immune system cells [2013-01]

C12N 2502/1107

. .

B cells [2013-01]

C12N 2502/1114

. .

T cells [2013-01]

C12N 2502/1121

. .

Dendritic cells [2013-01]

C12N 2502/1128

. .

Erythrocytes [2013-01]

C12N 2502/1135

. .

Granulocytes [2013-01]

C12N 2502/1142

. .

Osteoclasts [2013-01]

C12N 2502/115

. .

Platelets, megakaryocytes [2013-01]

C12N 2502/1157

. .

Monocytes, macrophages [2013-01]

C12N 2502/1164

. .

NK cells [2013-01]

C12N 2502/1171

. .

Haematopoietic stem cells [2013-01]

C12N 2502/1178

. .

Spleen cells [2013-01]

C12N 2502/1185

. .

Thymus cells [2013-01]

C12N 2502/1192

. .

Lymphatic cells [2013-01]

C12N 2502/13

connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" [2013-01]

C12N 2502/1305

. .

Adipocytes [2013-01]

C12N 2502/1311

. .

Osteocytes, osteoblasts, odontoblasts [2013-01]

C12N 2502/1317

. .

Chondrocytes [2013-01]

C12N 2502/1323

. .

Adult fibroblasts [2013-01]

C12N 2502/1329

. .

Cardiomyocytes [2013-01]

C12N 2502/1335

. .

Skeletal muscle cells, myocytes, myoblasts, myotubes [2013-01]

C12N 2502/1341

. .

Tenocytes, cells from tendons and ligaments [2013-01]

C12N 2502/1347

. .

Smooth muscle cells [2013-01]

C12N 2502/1352

. .

Mesenchymal stem cells [2013-01]

C12N 2502/1358

. . .

Bone marrow mesenchymal stem cells (BM-MSC) [2013-01]

C12N 2502/1364

. . .

Dental pulp stem cells, dental follicle stem cells [2013-01]

C12N 2502/137

. . .

Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood [2013-01]

C12N 2502/1376

. . .

Mesenchymal stem cells from hair follicles [2013-01]

C12N 2502/1382

. . .

Adipose-derived stem cells [ADSC], adipose stromal stem cells [2013-01]

C12N 2502/1388

. . .

Mesenchymal stem cells from other natural sources [2013-01]

C12N 2502/1394

. .

Bone marrow stromal cells; whole marrow [2013-01]

C12N 2502/14

hepatocytes [2013-01]

C12N 2502/22

pancreatic cells [2013-01]

C12N 2502/23

Gastro-intestinal tract cells [2013-01]

C12N 2502/24

Genital tract cells, non-germinal cells from gonads [2013-01]

C12N 2502/243

. .

Cells of the female genital tract, non-germinal ovarian cells [2013-01]

C12N 2502/246

. .

Cells of the male genital tract, non-germinal testis cells [2013-01]

C12N 2502/25

Urinary tract cells, renal cells [2013-01]

C12N 2502/253

. .

Bladder cells [2013-01]

C12N 2502/256

. .

Renal cells [2013-01]

C12N 2502/27

Lung cells, respiratory tract cells [2013-01]

C12N 2502/28

Vascular endothelial cells [2013-01]

C12N 2502/30

tumour cells [2013-01]

C12N 2502/45

Artificially induced pluripotent stem cells [2013-01]

C12N 2502/50

invertebrate cells [2013-01]

C12N 2502/70

Non-animal cells [2013-01]

C12N 2502/99

genetically modified cells [2013-01]

NOTE

Use C12N 2501/00 to index the expressed products.

C12N 2503/00

Use of cells in diagnostics [2013-01]

C12N 2503/02

Drug screening [2013-01]

C12N 2503/04

Screening or testing on artificial tissues [2013-01]

C12N 2503/06

. .

Screening or testing on artificial skin [2013-01]

C12N 2506/00

Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells [2013-01]

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N 5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

C12N 2506/02

from embryonic cells [2013-01]

C12N 2506/025

. .

from extra-embryonic cells, e.g. trophoblast, placenta [2013-01]

C12N 2506/03

from non-embryonic pluripotent stem cells [2013-01]

C12N 2506/04

from germ cells [2013-01]

C12N 2506/07

from endocrine cells [2013-01]

C12N 2506/072

. .

from adrenal cells [2013-01]

C12N 2506/074

. .

from pinealocytes [2013-01]

C12N 2506/076

. .

from pituitary cells [2013-01]

C12N 2506/078

. .

from thyroid, parathyroid cells [2013-01]

C12N 2506/08

from cells of the nervous system [2013-01]

C12N 2506/09

from epidermal cells, from skin cells, from oral mucosa cells [2013-01]

C12N 2506/091

. .

from melanocytes [2013-01]

C12N 2506/092

. .

from hair cells [2013-01]

C12N 2506/094

. .

from keratinocytes [2013-01]

C12N 2506/095

. .

from mammary cells [2013-01]

C12N 2506/097

. .

from oral mucosa cells [2013-01]

C12N 2506/098

. .

from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013-01]

C12N 2506/11

from blood or immune system cells [2013-01]

C12N 2506/115

. .

from monocytes, from macrophages [2013-01]

C12N 2506/13

from connective tissue cells, from mesenchymal cells [2013-01]

C12N 2506/1307

. .

from adult fibroblasts [2013-01]

C12N 2506/1315

. .

from cardiomyocytes [2013-01]

C12N 2506/1323

. .

from skeletal muscle cells [2013-01]

C12N 2506/133

. .

from tenocytes [2013-01]

C12N 2506/1338

. .

from smooth muscle cells [2013-01]

C12N 2506/1346

. .

from mesenchymal stem cells [2013-01]

C12N 2506/1353

. . .

from bone marrow mesenchymal stem cells (BM-MSC) [2013-01]

C12N 2506/1361

. . .

from dental pulp or dental follicle stem cells [2013-01]

C12N 2506/1369

. . .

from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood [2013-01]

C12N 2506/1376

. . .

from mesenchymal stem cells derived from hair follicles [2013-01]

C12N 2506/1384

. . .

from adipose-derived stem cells [ADSC], from adipose stromal stem cells [2013-01]

C12N 2506/1392

. . .

from mesenchymal stem cells from other natural sources [2013-01]

C12N 2506/14

from hepatocytes [2013-01]

C12N 2506/22

from pancreatic cells [2013-01]

C12N 2506/23

from cells of the gastro-intestinal tract [2013-01]

C12N 2506/24

from cells of the genital tract, from non-germinal gonad cells [2013-01]

C12N 2506/243

. .

from cells of the female genital tract cells, from non-germinal ovarian cells [2013-01]

C12N 2506/246

. .

from cells of the male genital tract cells, from non-germinal testis cells [2013-01]

C12N 2506/25

from renal cells, from cells of the urinary tract [2013-01]

C12N 2506/27

from lung cells, from cells of the respiratory tract [2013-01]

C12N 2506/28

from vascular endothelial cells [2013-01]

C12N 2506/30

from cancer cells, e.g. reversion of tumour cells [2013-01]

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693.

C12N 2506/45

from artificially induced pluripotent stem cells [2013-01]

C12N 2509/00

Methods for the dissociation of cells, e.g. specific use of enzymes [2013-01]

C12N 2509/10

Mechanical dissociation [2013-01]

C12N 2510/00

Genetically modified cells [2013-01]

C12N 2510/02

Cells for production [2013-01]

C12N 2510/04

Immortalised cells [2013-01]

C12N 2511/00

Cells for large scale production [2013-01]

C12N 2513/00

3D culture [2013-01]

C12N 2517/00

Cells related to new breeds of animals [2013-01]

C12N 2517/02

Cells from transgenic animals [2013-01]

C12N 2517/04

Cells produced using nuclear transfer [2013-01]

C12N 2517/10

Conditioning of cells for in vitro fecondation or nuclear transfer [2013-01]

C12N 2521/00

Culture process characterised by the use of hydrostatic pressure, flow or shear forces [2013-01]

C12N 2521/10

Sound, e.g. ultrasounds [2013-01]

C12N 2523/00

Culture process characterised by temperature [2013-01]

C12N 2525/00

Culture process characterised by gravity, e.g. microgravity [2013-01]

C12N 2527/00

Culture process characterised by the use of mechanical forces, e.g. strain, vibration [2013-01]

C12N 2529/00

Culture process characterised by the use of electromagnetic stimulation [2013-01]

C12N 2529/10

Stimulation by light [2013-01]

C12N 2531/00

Microcarriers [2013-01]

C12N 2533/00

Supports or coatings for cell culture, characterised by material [2013-01]

C12N 2533/10

Mineral substrates [2013-01]

C12N 2533/12

. .

Glass [2013-01]

C12N 2533/14

. .

Ceramic [2013-01]

C12N 2533/18

. .

Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells [2013-01]

C12N 2533/20

Small organic molecules [2013-01]

C12N 2533/30

Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10) [2013-01]

C12N 2533/32

. .

Polylysine, polyornithine [2013-01]

C12N 2533/40

. .

Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers [2013-01]

C12N 2533/50

Proteins [2013-01]

C12N 2533/52

. .

Fibronectin; Laminin [2013-01]

C12N 2533/54

. .

Collagen; Gelatin [2013-01]

C12N 2533/56

. .

Fibrin; Thrombin [2013-01]

C12N 2533/70

Polysaccharides [2013-01]

C12N 2533/72

. .

Chitin, chitosan [2013-01]

C12N 2533/74

. .

Alginate [2013-01]

C12N 2533/76

. .

Agarose, agar-agar [2013-01]

C12N 2533/78

. .

Cellulose [2013-01]

C12N 2533/80

. .

Hyaluronan [2013-01]

C12N 2533/90

Substrates of biological origin, e.g. extracellular matrix, decellularised tissue [2013-01]

C12N 2533/92

. .

Amnion; Decellularised dermis or mucosa [2013-01]

C12N 2535/00

Supports or coatings for cell culture characterised by topography [2013-01]

C12N 2535/10

Patterned coating [2013-01]

C12N 2537/00

Supports and/or coatings for cell culture characterised by physical or chemical treatment [2013-01]

C12N 2537/10

Cross-linking [2013-01]

C12N 2539/00

Supports and/or coatings for cell culture characterised by properties [2013-01]

C12N 2539/10

Coating allowing for selective detachment of cells, e.g. thermoreactive coating [2013-01]

Viruses [2022-02]

C12N 2710/00

dsDNA viruses [2022-02]

C12N 2710/00011

Details [2022-02]

C12N 2710/00021

. .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/00022

. .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/00023

. .

Virus like particles [VLP] [2013-01]

C12N 2710/00031

. .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/00032

. .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/00033

. .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/00034

. .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/00041

. .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/00042

. . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/00043

. . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/00044

. . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/00045

. . .

Special targeting system for viral vectors [2013-01]

C12N 2710/00051

. .

Methods of production or purification of viral material [2013-01]

C12N 2710/00052

. . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/00061

. .

Methods of inactivation or attenuation [2013-01]

C12N 2710/00062

. . .

by genetic engineering [2013-01]

C12N 2710/00063

. . .

by chemical treatment [2013-01]

C12N 2710/00064

. . .

by serial passage [2013-01]

C12N 2710/00071

. .

Demonstrated in vivo effect [2013-01]

C12N 2710/00088

. .

for redistribution [2022-02]

C12N 2710/10011

. .

Adenoviridae [2013-01]

C12N 2710/10021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/10022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/10023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/10031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/10032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/10033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/10034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/10041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/10042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/10043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/10044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/10045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/10051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/10052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/10061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/10062

. . . .

by genetic engineering [2013-01]

C12N 2710/10063

. . . .

by chemical treatment [2013-01]

C12N 2710/10064

. . . .

by serial passage [2013-01]

C12N 2710/10071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/10088

. . .

for redistribution [2022-02]

C12N 2710/10111

. . .

Atadenovirus, e.g. ovine adenovirus D [2013-01]

C12N 2710/10121

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/10122

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/10123

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/10131

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/10132

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/10133

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/10134

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/10141

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/10142

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/10143

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/10144

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/10145

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/10151

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/10152

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/10161

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/10162

. . . . .

by genetic engineering [2013-01]

C12N 2710/10163

. . . . .

by chemical treatment [2013-01]

C12N 2710/10164

. . . . .

by serial passage [2013-01]

C12N 2710/10171

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/10188

. . . .

for redistribution [2022-02]

C12N 2710/10211

. . .

Aviadenovirus, e.g. fowl adenovirus A [2013-01]

C12N 2710/10221

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/10222

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/10223

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/10231

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/10232

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/10233

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/10234

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/10241

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/10242

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/10243

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/10244

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/10245

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/10251

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/10252

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/10261

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/10262

. . . . .

by genetic engineering [2013-01]

C12N 2710/10263

. . . . .

by chemical treatment [2013-01]

C12N 2710/10264

. . . . .

by serial passage [2013-01]

C12N 2710/10271

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/10288

. . . .

for redistribution [2022-02]

C12N 2710/10311

. . .

Mastadenovirus, e.g. human or simian adenoviruses [2013-01]

C12N 2710/10321

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/10322

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/10323

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/10331

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/10332

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/10333

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/10334

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/10341

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/10342

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/10343

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/10344

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/10345

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/10351

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/10352

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/10361

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/10362

. . . . .

by genetic engineering [2013-01]

C12N 2710/10363

. . . . .

by chemical treatment [2013-01]

C12N 2710/10364

. . . . .

by serial passage [2013-01]

C12N 2710/10371

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/10388

. . . .

for redistribution [2022-02]

C12N 2710/12011

. .

Asfarviridae [2013-01]

C12N 2710/12021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/12022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/12023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/12031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/12032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/12033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/12034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/12041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/12042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/12043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/12044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/12045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/12051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/12052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/12061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/12062

. . . .

by genetic engineering [2013-01]

C12N 2710/12063

. . . .

by chemical treatment [2013-01]

C12N 2710/12064

. . . .

by serial passage [2013-01]

C12N 2710/12071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/12088

. . .

for redistribution [2022-02]

C12N 2710/14011

. .

Baculoviridae [2013-01]

C12N 2710/14021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/14022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/14023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/14031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/14032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/14033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/14034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/14041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/14042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/14043

. . . .

viral genome or elements thereof as genetic vectore [2013-01]

C12N 2710/14044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/14045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/14051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/14052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/14061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/14062

. . . .

by genetic engineering [2013-01]

C12N 2710/14063

. . . .

by chemical treatment [2013-01]

C12N 2710/14064

. . . .

by serial passage [2013-01]

C12N 2710/14071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/14088

. . .

for redistribution [2022-02]

C12N 2710/14111

. . .

Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus [2013-01]

C12N 2710/14121

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/14122

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/14123

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/14131

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/14132

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/14133

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/14134

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/14141

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/14142

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/14143

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/14144

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/14145

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/14151

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/14152

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/14161

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/14162

. . . . .

by genetic engineering [2013-01]

C12N 2710/14163

. . . . .

by chemical treatment [2013-01]

C12N 2710/14164

. . . . .

by serial passage [2013-01]

C12N 2710/14171

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/14188

. . . .

For redistribution [2013-01]

C12N 2710/16011

. .

Herpesviridae [2013-01]

C12N 2710/16021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/16031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16062

. . . .

by genetic engineering [2013-01]

C12N 2710/16063

. . . .

by chemical treatment [2013-01]

C12N 2710/16064

. . . .

by serial passage [2013-01]

C12N 2710/16071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16088

. . .

for redistribution [2022-02]

C12N 2710/16111

. . .

Cytomegalovirus, e.g. human herpesvirus 5 [2013-01]

C12N 2710/16121

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16122

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16123

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16131

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16132

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16133

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16134

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16141

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16142

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16143

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16144

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16145

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16151

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16152

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16161

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16162

. . . . .

by genetic engineering [2013-01]

C12N 2710/16163

. . . . .

by chemical treatment [2013-01]

C12N 2710/16164

. . . . .

by serial passage [2013-01]

C12N 2710/16171

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16188

. . . .

for redistribution [2022-02]

C12N 2710/16211

. . .

Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus [2013-01]

C12N 2710/16221

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2017-02]

C12N 2710/16222

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16223

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16231

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16232

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16233

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16234

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16241

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16242

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16243

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16244

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16245

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16251

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16252

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16261

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16262

. . . . .

by genetic engineering [2013-01]

C12N 2710/16263

. . . . .

by chemical treatment [2013-01]

C12N 2710/16264

. . . . .

by serial passage [2013-01]

C12N 2710/16271

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16288

. . . .

for redistribution [2022-02]

C12N 2710/16311

. . .

Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV [2013-01]

C12N 2710/16321

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16322

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16323

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16331

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16332

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16333

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16334

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16341

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16342

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16343

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16344

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16345

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16351

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16352

. . . . .

relating to complementin g cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16361

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16362

. . . . .

by genetic engineering [2013-01]

C12N 2710/16363

. . . . .

by chemical treatment [2013-01]

C12N 2710/16364

. . . . .

by serial passage [2013-01]

C12N 2710/16371

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16388

. . . .

for redistribution [2022-02]

C12N 2710/16411

. . .

Rhadinovirus, e.g. human herpesvirus 8 [2013-01]

C12N 2710/16421

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16422

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16423

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16431

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16432

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16433

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16434

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16441

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16442

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16443

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16444

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16445

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16451

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16452

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16461

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16462

. . . . .

by genetic engineering [2013-01]

C12N 2710/16463

. . . . .

by chemical treatment [2013-01]

C12N 2710/16464

. . . . .

by serial passage [2013-01]

C12N 2710/16471

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16488

. . . .

for redistribution [2022-02]

C12N 2710/16511

. . .

Roseolovirus, e.g. human herpesvirus 6, 7 [2013-01]

C12N 2710/16521

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16522

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16523

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16531

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16532

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16533

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16534

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral [2013-01]

C12N 2710/16541

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16542

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16543

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16544

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16545

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16551

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16552

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16561

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16562

. . . . .

by genetic engineering [2013-01]

C12N 2710/16563

. . . . .

by chemical treatment [2013-01]

C12N 2710/16564

. . . . .

by serial passage [2013-01]

C12N 2710/16571

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16588

. . . .

for redistribution [2022-02]

C12N 2710/16611

. . .

Simplexvirus, e.g. human herpesvirus 1, 2 [2013-01]

C12N 2710/16621

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16622

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16623

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16631

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16632

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16633

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16634

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16641

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16642

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16643

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16644

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16645

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16651

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16652

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16661

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16662

. . . . .

by genetic engineering [2013-01]

C12N 2710/16663

. . . . .

by chemical treatment [2013-01]

C12N 2710/16664

. . . . .

by serial passage [2013-01]

C12N 2710/16671

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16688

. . . .

for redistribution [2022-02]

C12N 2710/16711

. . .

Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies [2013-01]

C12N 2710/16721

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/16722

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/16723

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/16731

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/16732

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/16733

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/16734

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/16741

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/16742

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/16743

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/16744

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/16745

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/16751

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/16752

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/16761

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/16762

. . . . .

by genetic engineering [2013-01]

C12N 2710/16763

. . . . .

by chemical treatment [2013-01]

C12N 2710/16764

. . . . .

by serial passage [2013-01]

C12N 2710/16771

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/16788

. . . .

for redistribution [2022-02]

C12N 2710/18011

. .

Nimaviridae [2013-01]

C12N 2710/18021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/18022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/18023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/18031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/18032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/18033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/18034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/18041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/18042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/18043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/18044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/18045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/18051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/18052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/18061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/18062

. . . .

by genetic engineering [2013-01]

C12N 2710/18063

. . . .

by chemical treatment [2013-01]

C12N 2710/18064

. . . .

by serial passage [2013-01]

C12N 2710/18071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/18088

. . .

for redistribution [2022-02]

C12N 2710/20011

. .

Papillomaviridae [2013-01]

C12N 2710/20021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/20022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/20023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/20031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/20032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/20033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/20034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/20041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/20042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/20043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/20044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/20045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/20051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/20052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/20061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/20062

. . . .

by genetic engineering [2013-01]

C12N 2710/20063

. . . .

by chemical treatment [2013-01]

C12N 2710/20064

. . . .

by serial passage [2013-01]

C12N 2710/20071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/20088

. . .

for redistribution [2022-02]

C12N 2710/22011

. .

Polyomaviridae, e.g. polyoma, SV40, JC [2013-01]

C12N 2710/22021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/22022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/22023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/22031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/22032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/22033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/22034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/22041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/22042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/22043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/22044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/22045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/22051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/22052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/22061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/22062

. . . .

by genetic engineering [2013-01]

C12N 2710/22063

. . . .

by chemical treatment [2013-01]

C12N 2710/22064

. . . .

by serial passage [2013-01]

C12N 2710/22071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/22088

. . .

for redistribution [2022-02]

C12N 2710/24011

. .

Poxviridae [2013-01]

C12N 2710/24021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/24022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/24023

. . .

Virus like particles [VLP] [2013-01]

C12N 2710/24031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/24032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/24033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/24034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/24041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/24042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/24043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/24044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/24045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/24051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2710/24052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/24061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/24062

. . . .

by genetic engineering [2013-01]

C12N 2710/24063

. . . .

by chemical treatment [2013-01]

C12N 2710/24064

. . . .

by serial passage [2013-01]

C12N 2710/24071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2710/24088

. . .

for redistribution [2022-02]

C12N 2710/24111

. . .

Orthopoxvirus, e.g. vaccinia virus, variola [2013-01]

C12N 2710/24121

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/24122

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/24123

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/24131

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/24132

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/24133

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/24134

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/24141

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/24142

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/24143

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/24144

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/24145

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/24151

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/24152

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/24161

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/24162

. . . . .

by genetic engineering [2013-01]

C12N 2710/24163

. . . . .

by chemical treatment [2013-01]

C12N 2710/24164

. . . . .

by serial passage [2013-01]

C12N 2710/24171

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/24188

. . . .

for redistribution [2022-02]

C12N 2710/24211

. . .

Parapoxvirus, e.g. Orf virus [2013-01]

C12N 2710/24221

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2710/24222

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2710/24223

. . . .

Virus like particles [VLP] [2013-01]

C12N 2710/24231

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2710/24232

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2710/24233

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2710/24234

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2710/24241

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2710/24242

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2710/24243

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2710/24244

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2710/24245

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2710/24251

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2710/24252

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2710/24261

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2710/24262

. . . . .

by genetic engineering [2013-01]

C12N 2710/24263

. . . . .

by chemical treatment [2013-01]

C12N 2710/24264

. . . . .

by serial passage [2013-01]

C12N 2710/24271

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2710/24288

. . . .

for redistribution [2022-02]

C12N 2720/00

dsRNA viruses [2022-02]

C12N 2720/00011

Details [2022-02]

C12N 2720/00021

. .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/00022

. .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/00023

. .

Virus like particles [VLP] [2013-01]

C12N 2720/00031

. .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/00032

. .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/00033

. .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/00034

. .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/00041

. .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2720/00042

. . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/00043

. . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/00044

. . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/00045

. . .

Special targeting system for viral vectors [2013-01]

C12N 2720/00051

. .

Methods of production or purification of viral material [2013-01]

C12N 2720/00052

. . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/00061

. .

Methods of inactivation or attenuation [2013-01]

C12N 2720/00062

. . .

by genetic engineering [2013-01]

C12N 2720/00063

. . .

by chemical treatment [2013-01]

C12N 2720/00064

. . .

by serial passage [2013-01]

C12N 2720/00071

. .

Demonstrated in vivo effect [2013-01]

C12N 2720/00088

. .

for redistribution [2022-02]

C12N 2720/10011

. .

Birnaviridae [2013-01]

C12N 2720/10021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/10022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/10023

. . .

Virus like particles [VLP] [2013-01]

C12N 2720/10031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/10032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/10033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/10034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/10041

. . .

Use of virus, viral particle or viral elements as a vector [2020-01]

C12N 2720/10042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/10043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/10044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/10045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2720/10051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2720/10052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/10061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2720/10062

. . . .

by genetic engineering [2013-01]

C12N 2720/10063

. . . .

by chemical treatment [2013-01]

C12N 2720/10064

. . . .

by serial passage [2013-01]

C12N 2720/10071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2720/10088

. . .

for redistribution [2022-02]

C12N 2720/12011

. .

Reoviridae [2013-01]

C12N 2720/12021

. . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/12022

. . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/12023

. . .

Virus like particles [VLP] [2013-01]

C12N 2720/12031

. . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/12032

. . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/12033

. . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/12034

. . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/12041

. . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2720/12042

. . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/12043

. . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/12044

. . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/12045

. . . .

Special targeting system for viral vectors [2013-01]

C12N 2720/12051

. . .

Methods of production or purification of viral material [2013-01]

C12N 2720/12052

. . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/12061

. . .

Methods of inactivation or attenuation [2013-01]

C12N 2720/12062

. . . .

by genetic engineering [2013-01]

C12N 2720/12063

. . . .

by chemical treatment [2013-01]

C12N 2720/12064

. . . .

by serial passage [2013-01]

C12N 2720/12071

. . .

Demonstrated in vivo effect [2013-01]

C12N 2720/12088

. . .

for redistribution [2022-02]

C12N 2720/12111

. . .

Orbivirus, e.g. bluetongue virus [2013-01]

C12N 2720/12121

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/12122

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/12123

. . . .

Virus like particles [VLP] [2013-01]

C12N 2720/12131

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/12132

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/12133

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/12134

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/12141

. . . .

Use of virus, viral particle or viral elements as a vector [2020-01]

C12N 2720/12142

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/12143

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/12144

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/12145

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2720/12151

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2720/12152

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/12161

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2720/12162

. . . . .

by genetic engineering [2013-01]

C12N 2720/12163

. . . . .

by chemical treatment [2013-01]

C12N 2720/12164

. . . . .

by serial passage [2013-01]

C12N 2720/12171

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2720/12188

. . . .

for redistribution [2022-02]

C12N 2720/12211

. . .

Orthoreovirus, e.g. mammalian orthoreovirus [2013-01]

C12N 2720/12221

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/12222

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/12223

. . . .

Virus like particles [VLP] [2013-01]

C12N 2720/12231

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/12232

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/12233

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/12234

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/12241

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2720/12242

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/12243

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/12244

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/12245

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2720/12251

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2720/12252

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/12261

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2720/12262

. . . . .

by genetic engineering [2013-01]

C12N 2720/12263

. . . . .

by chemical treatment [2013-01]

C12N 2720/12264

. . . . .

by serial passage [2013-01]

C12N 2720/12271

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2720/12288

. . . .

for redistribution [2022-02]

C12N 2720/12311

. . .

Rotavirus, e.g. rotavirus A [2013-01]

C12N 2720/12321

. . . .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2720/12322

. . . .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2720/12323

. . . .

Virus like particles [VLP] [2013-01]

C12N 2720/12331

. . . .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]

C12N 2720/12332

. . . .

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01]

C12N 2720/12333

. . . .

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01]

C12N 2720/12334

. . . .

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01]

C12N 2720/12341

. . . .

Use of virus, viral particle or viral elements as a vector [2013-01]

C12N 2720/12342

. . . . .

virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01]

C12N 2720/12343

. . . . .

viral genome or elements thereof as genetic vector [2013-01]

C12N 2720/12344

. . . . .

Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01]

C12N 2720/12345

. . . . .

Special targeting system for viral vectors [2013-01]

C12N 2720/12351

. . . .

Methods of production or purification of viral material [2013-01]

C12N 2720/12352

. . . . .

relating to complementing cells and packaging systems for producing virus or viral particles [2013-01]

C12N 2720/12361

. . . .

Methods of inactivation or attenuation [2013-01]

C12N 2720/12362

. . . . .

by genetic engineering [2013-01]

C12N 2720/12363

. . . . .

by chemical treatment [2013-01]

C12N 2720/12364

. . . . .

by serial passage [2013-01]

C12N 2720/12371

. . . .

Demonstrated in vivo effect [2013-01]

C12N 2720/12388

. . . .

for redistribution [2022-02]

C12N 2730/00

Reverse transcribing DNA viruses [2022-02]

C12N 2730/00011

Details [2022-02]

C12N 2730/00021

. .

Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01]

C12N 2730/00022

. .

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01]

C12N 2730/00023

. .

Virus like particles [VLP] [2013-01]

C12N 2730/00031

. .

Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01]